Anti-c-reactive protein single-domain antibodies
Anti-CRP single-domain antibodies with controlled binding kinetics enable continuous monitoring of CRP levels, addressing the limitations of existing methods by allowing dynamic range detection and reducing medication side effects through precise inflammation status assessment.
Patent Information
- Application Number
- PCT/EP2024/062989
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for detecting and monitoring C-reactive protein (CRP) levels are limited by high-affinity antibodies that cause permanent binding, leading to sensor saturation and inability to continuously monitor dynamic CRP levels, which is essential for precise inflammation status assessment and therapeutic outcome evaluation.
Development of anti-CRP single-domain antibodies (sdAbs) with specific on-rate and off-rate constants, allowing for continuous association and dissociation with CRP, enabling continuous measurement of CRP levels over time and across a dynamic range, suitable for use in biosensors.
Enables precise detection and quantification of CRP levels from baseline to severe inflammation, facilitating targeted therapy and reducing medication side effects by allowing continuous monitoring of CRP levels, thereby improving therapeutic outcomes.
Smart Images

Figure IMGF000016_0001 
Figure IMGF000016_0002 
Figure IMGF000017_0001
Abstract
Description
[0001]New PCT-Patent Application Seerave Enterprises Limited, Christopher Rees Vossius Ref.: AF2045 PCT BS Anti-C-reactive protein single-domain antibodies The present invention relates to single-domain antibodies (sdAbs) binding C-reactive protein (CRP). In particular, the invention relates to sdAbs that bind CRP within a specific range of an on-rate constant and off-rate constant. The sdAbs of the present invention can associate and dissociate with CRP in a continuous manner. The invention further relates to nucleic acids encoding anti-CRP sdAbs, methods for detecting CRP, treatments and diagnoses making use of the anti-CRP sdAbs, methods for monitoring CRP levels and apparatuses comprising the anti-CRP sdAbs. Single-domain antibodies (sdAb) are a type of antibody fragment consisting of a single monomeric variable antibody domain only. Similarly, to their larger counterparts they are able to selectively bind to a specific antigen. sdAb can, e.g. be engineered from heavy-chain antibodies in camelids, referred to as VHH fragments. An advantage when using sdAbs is that they can be designed to not affect the biological activity or structure of a bound molecule. However, they may also be specifically designed to block biological activity. Further, sdAbs are particularly robust which is advantageous for e.g. application as biosensors or as components of biosensors. Thus, sdAbs are advantageous to specifically detect a molecule of interest with or without interfering with biological functions, e.g. as or in a biosensor. C-reactive protein (CRP) is an annular, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin 6 secretion by macrophages and T cells. The pathological significance of CRP for various diseases has been indicated in numerous studies, including metabolic syndrome, cardiovascular disease, active inflammatory bowel disease, cholecystitis, chronic obstructive pulmonary disease, acute bronchitis, sepsis, active advanced cancer, metastasis, pancreatitis, pneumonia, severe infection (lung, urinary, skin, gastrointestinal, blood), rheumatologic causes, and advanced tumors. The treatment of such diseases with drugs preferably results in reduced inflammation, i.e. a reduced level of CRP in a subject, for example reduced to the upper limit of normal (ULN) in a healthy non- inflammatory subject avoiding excessive tissue damage. To achieve this and to avoid overdosing or underdosing of drugs that may invoke adverse effects or result in an ineffective therapy, precise monitoring of CRP levels in a subject is desired. In addition, monitoring of CRP levels is useful to assess the therapeutic outcome of a potential treatment and whether a subject is for example incompatible with a treatment resulting in inflammation after drug administration. To achieve the above, precise measurement of CRP levels, preferably over an extended period of time, i.e. continuous monitoring of CRP levels is needed. However, the current means for detecting CRP are limited to antibodies with exceptionally high affinities to CRP which do however not consider the dynamic range of CRP levels in a subject and are not feasible for use in a biosensor. For example, Oloketuyi, et al. (2021) discloses anti-CRP nanobodies. HyTest ("HyTest, TechNotes: Human C-Reactive Protein) discloses anti-CRP monoclonal antibodies. A very high affinity CRP antibody results in a permanent binding of CRP which would saturate a biosensor. A saturated biosensor is unable to continuously monitor levels of CRP thereby rendering the same useless for measurements over time. When using a very high affinity CRP antibody, detection of CRP is limited to a yes, no type of spot measurement of CRP which does not allow for continuously monitoring dynamic levels of CRP that may be specific for certain diseases and therapies. Accordingly, there is a need for continuous monitoring of dynamic CRP levels, e.g. in a subject undergoing therapy or in a subject suffering from a disease. The technical problem underlying the present invention is the provision of means and methods for the detection, quantification and / or the monitoring of CRP, particularly continuous detection, quantification and / or monitoring. The technical problem is solved by provision of the embodiments characterized in the claims and as provided herein below. Specifically, the technical problem is solved, and the above-mentioned difficulties are overcome by the provision of an anti-CRP sdAb. The inventors have predicted the dynamic range of CRP levels in the context of disease and homeostasis, i.e. in a healthy context. They have shown that means for detecting, quantifying and monitoring CRP should cover said dynamic range to allow for an unambiguous conclusion about the inflammation status in a subject. The inventors have used the dynamic range of CRP to specifically generate sdAb that are capable of detecting CRP throughout the entire range, which allows detection and monitoring of the CRP level and thus the inflammation status in a subject or sample. In addition, the sdAb of the present invention embody a specific on-rate constant and off-rate constant, allowing for continuous association and dissociation with CRP, thereby enabling continuous measurement of CRP levels over time. The invention, inter alia, provides the following advantages: • Anti-CRP sdAb specifically associate with CRP over the entire dynamic range of CRP allowing for precise detection and quantification of the CRP level and thus inflammation status that is relevant in therapy. • The anti-CRP sdAbs can detect CRP from baseline CRP levels to CRP levels being present in severe inflammation. • The anti-CRP sdAbs can continuously and repeatedly bind CRP allowing for continuous detection, quantification and monitoring of CRP levels, e.g. when applied as a biosensor or as an implanted biosensor in a sample or subject, thereby overcoming extensive and laborious CRP spot measurements. • The dynamic detection of CRP levels contributes to the assessment of the therapeutic outcome of a treatment, or a possible adverse effect invoked by an intolerance to a drug. • The detection and quantification of CRP levels over time allow for targeted therapy of inflammatory diseases, thereby reducing the amount of medication and potential side effects of said medication • The anti-CRP sdAbs can be used as a biosensor in a device that allows for continuous monitoring of CRP levels in a subject. The invention provides the following items: 1. An anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3 x 10^-9 s-1– 2.5 x 10^-1 s-1(preferably an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 2.20 x 10^-1 s-1, preferably wherein said sdAb is capable of detecting and / or quantifying CRP concentrations of about 0.01 µM or less to about 1 µM or more. 2. The anti-CRP sdAb of item 1, wherein the sdAb comprises a first complementary determining region (CDR1), a second CDR (CDR2) and third CDR (CDR3), wherein: (i) CDR1 comprises SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions; or (ii) CDR1 comprises SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions; or (iii) CDR1 comprises SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions; or (iv) CDR1 comprises SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions; or (v) CDR1 comprises SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions; or (vi) CDR1 comprises SEQ ID NO: 43 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 45 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 47 or a variant thereof having up to five amino acid substitutions; (vii) CDR1 comprises SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions; or (viii) CDR1 comprises SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions; or (ix) CDR1 comprises SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions; or (x) CDR1 comprises SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions; or (xi) CDR1 comprises SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions. The anti-CRP sdAb of item 1 or 2, wherein the sdAb comprises a first framework region (FR1), a second framework region (FR2) and third framework region (FR3), wherein: (i) FR1 comprises SEQ ID NO: 2 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 4 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 6 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 8 or a variant thereof having up to three amino acid substitutions; or (ii) FR1 comprises SEQ ID NO: 10 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 12 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 14 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 16 or a variant thereof having up to three amino acid substitutions; or (iii) FR1 comprises SEQ ID NO: 18 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 20 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 22 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 24 or a variant thereof having up to three amino acid substitutions; or (iv) FR1 comprises SEQ ID NO: 26 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 28 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 30 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 32 or a variant thereof having up to three amino acid substitutions; or (v) FR1 comprises SEQ ID NO: 34 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 36 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 38 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 40 or a variant thereof having up to three amino acid substitutions; or (vi) FR1 comprises SEQ ID NO: 42 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 44 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 46 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 48 or a variant thereof having up to three amino acid substitutions; or (vii) FR1 comprises SEQ ID NO: 50 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 52 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 54 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 56 or a variant thereof having up to three amino acid substitutions; (viii) FR1 comprises SEQ ID NO: 58 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 60 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 62 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 64 or a variant thereof having up to three amino acid substitutions; or (ix) FR1 comprises SEQ ID NO: 66 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 68 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 70 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 72 or a variant thereof having up to three amino acid substitutions; or (x) FR1 comprises SEQ ID NO: 74 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 76 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 78 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 80 or a variant thereof having up to three amino acid substitutions; or (xi) FR1 comprises SEQ ID NO: 82 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 84 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 86 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 88 or a variant thereof having up to three amino acid substitutions; or (xii) FR1 comprises SEQ ID NO: 90 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 92 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 94 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 96 or a variant thereof having up to three amino acid substitutions. The anti-CRP sdAb of any one of items 1 to 3, wherein the sdAb comprises any one of (i) SEQ ID NO: 1 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 1; or (ii) SEQ ID NO: 9 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 9; or (iii) SEQ ID NO: 17 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 17; or (iv) SEQ ID NO: 25 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 25; or (v) SEQ ID NO: 33 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 33; or (vi) SEQ ID NO: 41 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 41; or (vii) SEQ ID NO: 49 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 49; or (viii) SEQ ID NO: 57 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 57; or (ix) SEQ ID NO: 65 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 65; or (x) SEQ ID NO: 73 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 73; or (xi) SEQ ID NO: 81 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 81; or (xii) SEQ ID NO: 89 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 89. The anti-CRP sdAb of any one of items 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 1.30 x 10^-2 s-1. The anti-CRP sdAb of any one of items 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 4.60 x 10^6 s-1M-1and an off-rate constant (koff) of about 2.60 x 10^-4 s-1– 2.20 x 10^-1 s-1. The anti-CRP sdAb of any one of items 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 4.10 x 10^4 s-1M-1– 3.80 x 10^5 s-1M-1and an off-rate constant (koff) of about 2.00 x 10^-5 s-1– 6.90 x 10^-3 s-1. The anti-CRP sdAb of any one of items 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.70 x 10^7 s-1M-1± 9.06 x 10^2 s- – 3.00 x 10^5 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 1.30 x 10^-2 s-1± 1.34 x 10^-7 s-1– 8.82 x 10^-5 s-1and optionally a KDof about 1.00 x 10^- 2 M – 9.62 M, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89. The anti-CRP sdAb of any one of items 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 4.10 x 10^4 s-1M-1– 3.80 x 10^5 s-1M-1± 3.31 x 10^2 s- – 1.48 x 10^4 s-1M-1and an off-rate constant (koff) of about 2.00 x 10^-5 s-1– 6.90 x 10^-3 s-1± 1.41 x 10^-6 s-1– 8.61 x 10^-5 s-1and optionally a KDof about 5.80 x 10^- 11 M – 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 49, 57, 65, 73, 81, 89. The anti-CRP sdAb of any one of items 1-9, wherein the anti-CRP sdAb continuously and reversibly binds CRP. The anti-CRP sdAb of any one of items 1-10, wherein the anti-CRP sdAb binds a second or further CRP after dissociating from a first CRP. The anti-CRP sdAb of any one of items 1-11, wherein the anti-CRP sdAb inhibits the biological function of CRP. The anti-CRP sdAb of any one of items 1-11, wherein the anti-CRP sdAb does not inhibit the biological function of CRP. The anti-CRP sdAb of item 12 or 13, wherein the biological function of CRP is CRP signalling or the CRP signalling pathway. The anti-CRP sdAb of any one of items 1-14, wherein the anti-CRP sdAb is conjugated to a biosensor electrode, such as a working electrode. The anti-CRP sdAb of item 15, wherein the anti-CRP sdAb is conjugated to a biosensor electrode via a linker, such as a nucleic acid. The anti-CRP sdAb of item 15 or 16, wherein the biosensor comprises one or more electrode, such as a working electrode and / or a counter electrode and / or a reference electrode, and a substrate. The anti-CRP sdAb of any one of items 15-17, wherein the biosensor comprises at least a working electrode and a substrate. The anti-CRP sdAb of any one of items 15-18, wherein the biosensor comprises an electrode comprising a conductive material such as carbon, metal, or metallic compound. The anti-CRP sdAb of any one of items 1-19, wherein the anti-CRP sdAb further comprises a detection label or tag. The anti-CRP sdAb of any one of items 1-19, wherein the anti-CRP sdAb does not comprise a detection label or tag. A nucleic acid encoding the anti-CRP sdAb of any one of items 1-21. A vector comprising the nucleic acid of item 22. The vector of item 23, wherein the vector is an expression vector. A method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of any one of items 1-21, and (ii) detecting binding of the anti-CRP sdAb. An in situ method for detecting and / or quantifying CRP in a subject, the method comprising (i) contacting a subject’s biological fluid with the anti-CRP sdAb of any one of items 1-21; and (ii) detecting binding of the anti-CRP sdAb. The method of item 25 or 26, further comprising detecting the binding of the anti-CRP sdAb over time. The method of any one of items 25-27, further comprising detecting the repeated binding of the anti-CRP sdAb over time. The method of any one of items 25-28, wherein binding of the anti-CRP sdAb is detected by a biosensor. The method of any one of items 25-29, wherein the sample comprises a biological fluid, such as a bodily fluid, for example interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva; or wherein the biological fluid is a bodily fluid, for example interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva. The method of any one of items 25-30, wherein the sample comprises human interstitial fluid (ISF), blood, urine, stool, serum, tear, sweat or saliva, or wherein the biological fluid is a human bodily fluid, for example human interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva. The method of any one of items 25and 27-29, wherein the sample comprises a sample from a biological production system such as a culture sample. The anti-CRP sdAb of any one of items 1-21 for use as a medicament. The anti-CRP sdAb of any one of items 1-21 for use in in vivo diagnosis. The anti-CRP sdAb of any one of items 1-21 for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation. A method of treatment a disease associated with an inflammation, optionally a systemic inflammation comprising a step of administering the anti-CRP sdAb of any one of items 1-21 to a subject in need thereof. The anti-CRP sdAb for use of item 35, or the method of item 36, wherein the disease is associated with an increased production or release of inflammatory markers. The anti-CRP sdAb for use of item 35 or 37, or the method of item 36 or 37, wherein the disease is associated with an increased production or release of CRP. The anti-CRP sdAb for use of any one of items 35 or 37-38, or the method of any one of items 36-38, wherein the disease is rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, or tumour. The anti-CRP sdAb of any one of items 1-21 for use in a method of in vivo diagnosis of a disease associated with an inflammation, optionally a systemic inflammation, the method comprising: (i) contacting a subject with the anti-CRP sdAb of any one of items 1-21, and (ii) detecting the binding of the anti-CRP sdAb. A method of in vivo diagnosis of a disease associated with an inflammation, optionally a systemic inflammation, the method comprising: (i) contacting a subject with the anti-CRP sdAb of any one of items 1-21, and (ii) detecting binding of the anti-CRP sdAb. An ex vivo or in vitro method of monitoring the level of CRP comprising: (i) contacting a sample of a subject with the anti-CRP sdAb of any one of items 1- 21, and (ii) detecting binding of the anti-CRP sdAb. A method of monitoring the level of CRP in a subject comprising: (i) contacting the subject with the anti-CRP sdAb of any one of items 1-21, and (ii) detecting binding of the anti-CRP sdAb. The anti-CRP sdAb for use of items 35 or 37-40, or the method of any one of items 36- 39 or 41-43, wherein binding of the anti-CRP sdAb is repeatedly detected over time. An apparatus comprising: (i) the anti-CRP sdAb of any one of items 1-21, and (ii) a contacting unit for contacting a sample or a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and optionally (iv) a dispensing unit for dispensing a drug, optionally wherein the drug is the anti- CRP sdAb of any one of items 1-21. The apparatus of item 45 for use in the treatment or in vivo diagnosis of a disease associated with an inflammation, optionally a systemic inflammation. The apparatus of item 45 or the apparatus for use of item 46, wherein the detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb comprises a biosensor. The apparatus or the apparatus for use of item 47, wherein the biosensor comprises one or more electrode, such as a working electrode and / or a counter electrode and / or a reference electrode, and a substrate, optionally wherein the sdAb is conjugated to the working electrode. The apparatus or the apparatus for use of item 47 or 48, wherein the biosensor comprises at least a working electrode and a substrate. The apparatus or the apparatus for use of any one of items 47-49, wherein the biosensor comprises an electrode comprising a conductive material such as carbon, a metal or metallic compound. The apparatus or the apparatus for use of any one of items 48-50, wherein the anti-CRP sdAb is layered on the one or more electrode or conjugated to the one or more electrode, preferably the working electrode and optionally, wherein the anti-CRP sdAb is conjugated to said electrode via a linker. The anti-CRP sdAb for use of item 35 or 40, or the method of item 36 or 41, or the apparatus for use of any one of items 46-51, wherein the disease is associated with an increased production or release of inflammatory markers. The anti-CRP sdAb for use of any one of items 35, 40 or 52, or the method of any one of items 36, 41 or 52, or the apparatus for use of any one of items 46-52, wherein the disease is associated with an increased production or release of CRP. The anti-CRP sdAb for use of any one of items 35, 40 or 52-53, or the method of any one of items 36, 41 or 52-53, or the apparatus of any one of items 46-53, wherein the disease is any one of rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, or tumour. A method of producing an anti-CRP sdAb comprising: (i) contacting a subject with a recombinant human CRP, and (ii) isolating a sdAb which successfully binds to CRP, and (iii) selecting for an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 2.20 x 10^-1 s-1. The method of item 55, wherein the method comprises selecting for an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 1.30 x 10^-2 s-1. The method of item 55, wherein the method comprises selecting for an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 4.60 x 10^6 s-1M-1and an off-rate constant (koff) of about 2.60 x 10^-4 s-1– 2.20 x 10^-1 s-1. The method of item 55, wherein the method comprises selecting for an on-rate constant (kon) of about 4.10 x 10^4 s-1M-1– 3.80 x 10^5 s-1M-1and an off-rate constant (koff) of about 2.00 x 10^-5 s-1– 6.90 x 10^-3 s-1. The method of any one of items 55-58, wherein the method further comprises a step of selecting for continuous and reversible binding to CRP. The method of any one of items 55-59, wherein the method further comprises a step of selecting for binding to a second or further CRP after dissociation from a first CRP. The method of any one of items 55-60, wherein the method further comprises a step of selecting for inhibiting the biological function of CRP or not inhibiting the biological function of CRP. The method of item 61, wherein the biological function of CRP is CRP signalling or the CRP signalling pathway. An anti-CRP sdAb produced by the method of any one of items 55-62. A biosensor comprising the anti-CRP sdAb of any one of items 1-21. The biosensor of item 64, wherein the biosensor comprises one or more biosensor electrodes. The biosensor of item 64 or 65, wherein the biosensor comprises a working electrode and a substrate The biosensor of item 66, wherein the biosensor further comprises a counter electrode and / or a reference electrode. The biosensor of any one of items 64-67, wherein the anti-CRP sdAb is conjugated to a biosensor electrode, optionally to a working electrode. The biosensor of item 68, wherein the anti-CRP sdAb is conjugated to a biosensor electrode, optionally to a working electrode, via a linker, such as a nucleic acid linker, amino acid / peptide linker, peptide nucleic acid linker, polymer linker, polyethylenglycol (PEG) linker, protein-tag linker, or conventional chemistry technique linker. 70. The biosensor of any one of items 66-69, wherein the working electrode comprises a conductive material, such as carbon, metal or metallic compound. 71. The biosensor of any one of items 64-70, wherein the biosensor, the anti-CRP sdAb or the linker comprises a detection label, a tag, or redox reporters / indicators. 72. The method of any one of items 25-32, 36-39 or 41-44, or the anti-CRP sdAb for use of any one of items 35, 37-40 or 44, wherein binding of the anti-CRP sdAb to CRP is detected and / or quantified by electrochemical ELISA. The present invention provides single-domain antibodies (sdAb) that specifically bind to C- reactive protein. The sdAb specifically binding CRP of the present invention may be referred to anti-CRP sdAb or anti-CRP VHH. Single-domain antibodies are also known as nanobodies. In the sense of the present invention a sdAb is the heavy chain variable domain of a single chain of a heavy-chain antibody. A heavy-chain antibody is an antibody which consists only of two heavy chains, each of which contain a heavy chain variable domain (VH). The sdAb of the present invention is preferably engineered from the heavy chain variable domain of a camelid heavy-chain antibody. The sdAbs of the present invention are particularly useful for detecting and monitoring the CRP level over time since they embody a kinetic binding range and allow for continuous association and dissociation within the dynamic range of CRP levels. The sdAb of the present invention have specifically been developed to be capable of detecting CRP throughout the relevant inflammation ranges. Thus, the inventors have found sdAb that can detect CRP levels from a baseline, e.g. in a healthy subject, to CRP levels present during severe inflammation. Consequently, the sdAb of the present invention allow for precise single or continuous, quantitative detection of CRP levels in all clinically relevant ranges of CRP levels. The sdAbs of the present invention can embody a specific on-rate constant (kon) and off-rate constant (koff). The kon(ka) describes the rate of complex formation, i.e. the number of sdAb- CRP complexes formed per second in a one molar solution of sdAb and CRP. The koff(kd) describes the rate or speed at which e.g. a ligand dissociates from a protein, such as a sdAb from CRP. The binding constant (also affinity constant or association constant) Kais defined as kon / koff. The dissociation constant KDis defined as 1 / Ka. Unless otherwise defined, the herein provided kon(ka) values are displayed / provided in the unit [s-1M-1]. Unless otherwise defined, the herein provided koff(kd) values are displayed / provided in the unit [s-1]. Unless otherwise defined, the herein provided dissociation constant KDvalues are displayed / provided in the unit [nM]. In the sense of the present invention, a sdAb can have a konand koffin a range that allows for continuous association and dissociation to CRP. The invention is not particularly limited to any sdAb having specific konor koffvalues, rather any sdAb having konand koffvalues that allow for association and dissociation to CRP can be used. Accordingly, the present invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3 x 10^-9 s-1– 2.5 x 10^-1 s-1(preferably an off- rate constant (koff) of about 3.20 x 10^-9 s-1– 2.20 x 10^-1 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement, and preferably wherein said sdAb is capable of detecting and / or quantifying CRP concentrations of about 0.01 µM or less to about 1 µM or more. In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise an on-rate constant (kon) of about or more than about 2.1 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 2.5 x 10^-9 s-1– 2 x 10^-2 s-1, particularly wherein the values are obtained by a SPR Biacore binding kinetic measurement (preferably on samples comprising purified sdAbs). Accordingly, the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising an on-rate constant (kon) about or more than about 2.1 x 10^5 s-1M-1. Preferably the lower limit is about 2.2 x 10^5 s-1M-1, 2.3 x 10^5 s-1M-1, 2.4 x 10^5 s-1M-1, 2.5 x 10^5 s-1M-1, 2.6 x 10^5 s-1M-1, 2.6 x 10^5 s-1M-1, 2.8 x 10^5 s-1M-1, 2.9 x 10^5 s-1M-1, more preferably about 3.0 x 10^5 s-1M-1, 3.1 x 10^5 s-1M-1, 3.2 x 10^5 s-1M-1, 3.3 x 10^5 s-1M-1, 3.4 x 10^5 s-1M-1, 3.5 x 10^5 s-1M-1, 3.6 x 10^5 s-1M-1, 3.7 x 10^5 s-1M-1, and most preferred about 3.8 x 10^5 s-1M-1(specifically about 3.80 x 10^5 s-1M-1). The lower limit may be about 4 x 10^5 (specifically about 6.00 x 10^5 (specifically about 8.00 x 10^5 s-1M-1), 9 x 10^5 s-1M-1, 1 x 10^6 s-1M-1(e.g., about 1.1 x 10^6 s-1M-1, specifically about 1.30 x 10^6 s-1M-1, specifically about 1.50 x 10^6 s-1M-1, specifically about 1.60 x 10^6 s-1M-1, specifically about 1.70 x 10^6 s-1M-1), 2 x 10^6 s-1M-1(e.g., about 2.05 x 10^6 s-1M-1, specifically about 2.10 x 10^6 s-1M-1, specifically about 2.40 x 10^6 s-1M-1, specifically about 2.70 x 10^6 s-1M-1), 3 x 10^6 s-1M-1, 4 x 10^6 s-1M-1, 5 x 10^6 s-1M-1, 6 x 10^6 s-1M-1, 7 x 10^6 s-1M-1, 8 x 10^6 s-1M-1, 9 x 10^6 s-1M-1, 1 x 10^7 s-1M-1, (e.g., about 1.1 x 10^7 s-1M-1, specifically about 1.70 x 10^7 s-1M-1). As also mentioned herein above and below, the herein provided sdAbs are, inter alia, particularly useful for their application in (in vitro and / or in vivo) diagnosis and / or diagnostic devices (such as biosensors) or for continuous monitoring of CRP levels. In this context, it is particularly useful that the sdAbs comprise fast association to and dissociation from the antigen (e.g., CRP). Accordingly, in the context of the present invention a particularly high on-rate constant (kon) is particularly advantageous. Accordingly, the upper limit of the on-rate constant (kon) of the herein provided anti-CRP sdAbs is not particularly limited. Nonetheless, the on-rate constant (kon) of the herein provided anti-CRP sdAbs may comprise an upper limit of about 3 x 10^7 s-1M-1. Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise an on-rate constant (kon) of about 3 x 10^5 s-1M-1– 9 x 10^9 s- and / or an off-rate constant (koff) of about 2.5 x 10^-9 s-1– 2 x 10^-2 s-1, particularly wherein the values are obtained by a SPR Biacore binding kinetic measurement (preferably on samples comprising purified sdAbs). More preferably, the upper limit is about 9 x 10^9 s-1M-1, 8 x 10^9 s-1M-1, 7 x 10^9 s-1M-1, 6 x even more preferably about 1.9 x 10^7 s-1M-1, 1.8 x 10^7 s-1M-1, and most preferably about 1.7 x 10^7 s-1M-1. In this context, the on-rate constant (kon) values are preferably determined using an SPR Biacore measurement (preferably on samples comprising purified sdAbs). Accordingly, the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising an off-rate constant (koff) of about 2.5 x 10^-9 s-1– 2 x 10^-2 s-1. Preferably the lower limit is about 2.6 x 10^-9 s-1, 2.7 x 10^-9 s-1, 2.8 x 10^-9 s-1, 2.9 x 10^-9 s-1, 3 x 10^-9 s-1, 3.1 x 10^-9 s-1, most preferred about 3.2 x 10^-9 s-1. The lower limit may be about 3.3 x 10^-9 s-1, 4 x 10^-9 s-1, 5 x 10^-9 s-1, 6.0 x 10^-9 s-1, 5.0 x 10^-9 s-1, 1.0 x 10^-8 s-1, 1.0 x 10^-7 s-1(e.g., 1.1 x 10^-7 s-1, specifically about 1.3 x 10^-7 s-1), 1.0 x 10^-6 s-1, 1.0 x 10^-5 s-1(e.g., about 1.1 x 10^-5 s-1, specifically about 2 x 10^-5 s-1), 6.0 x 10^-5 s-1(e.g., about 6.1 x 10^-5 s-1, specifically about 6.2 x 10^-5 s-1), 7.0 x 10^-5 s-1, 8.0 x 10^-5 s-1(e.g., about 8.01 x 10^-5 s-1, specifically about 8.1 x 10^-5 s-1), 9.0 x 10^-5 s-1(e.g., about 9.1 x 10^-5 s-1, specifically about 9.8 x 10^-5 s-1). More preferably, the upper limit is about 2 x 10^-2 s-1, 1.9 x 10^-2 s-1, 1.8 x 10^-2 s-1, 1.7 x 10^-2 s-1, 1.6 x 10^-2 s-1, 1.5 x 10^-2 s-1, 1.4 x 10^-2 s-1, (preferably about 1.3 x 10^-2 s-1). Even more preferably, the upper limit is about 1 x 10^-2 s-1, 9 x 10^-3 s-1, 8 x 10^-3 s-1, 7 x 10^-3 s-1, 6 x 10^-3 s-1, 5 x 10^-3 s-1, 4 x 10^-3 s-1, 3 x 10^-3 s-1, 2 x 10^-3 s-1, (specifically about 1.9 x 10^-3 s-1or specifically about 1.3 x 10^-3 s-1), 1 x 10^-3 s-1, 9 x 10^-4 s-1, 8 x 10^- 4 s-1, 7 x 10^-4 s-1, 6 x 10^-4 s-1, 5 x 10^-4 s-1, 4 x 10^-4 s-1(specifically about 3 x 10^-4 s-1), 2.9 x 10^-4 s-1, 2.8 x 10^-4 s-1, 2.7 x 10^-4 s-1, 2.6 x 10^-4 s-1(specifically about 2.5 x 10^-4 s-1), 2.4 x 10^-4 s-1, 2.3 x 10^-4 s-1, 2.2 x 10^-4 s-1, 2.1 x 10^-4 s-1, 2.0 x 10^-4 s-1, 1.9 x 10^-4 s-1, 1.8 x 10^-4 s-1(specifically about 1.7 x 10^-4 s-1). In this context, the off-rate constant (koff) values are preferably determined using an SPR Biacore measurement (preferably on samples comprising purified sdAbs). In particular, the present invention provides for anti-CRP sdAb SCR-3E4 (or variants thereof), comprising an on-rate constant (kon) of about 3.8 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 6.2 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3G7 (or variants thereof), comprising an on-rate constant (kon) of about 6 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 9.8 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-2D1 (or variants thereof), comprising an on-rate constant (kon) of about 8 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 3 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-1A1 (or variants thereof), comprising an on-rate constant (kon) of about 1.3 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 1.3 x 10^-2 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3B7 (or variants thereof), comprising an on-rate constant (kon) of about 1.5 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 1.3 x 10^-7 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-2D2 (or variants thereof), comprising an on-rate constant (kon) of about 1.6 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 2 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3E5 (or variants thereof), comprising an on-rate constant (kon) of about 1.7 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 3.2 x 10^-9 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-2B4 (or variants thereof), comprising an on-rate constant (kon) of about 1.7 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 1.7 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3H1 (or variants thereof), comprising an on-rate constant (kon) of about 2.1 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 2.5 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3H6 (or variants thereof), comprising an on-rate constant (kon) of about 2.4 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 8.1 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3A4 (or variants thereof), comprising an on-rate constant (kon) of about 2.7 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 1.9 x 10^-3 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3A5 (or variants thereof), comprising an on-rate constant (kon) of about 1.7 x 10^7 s-1M-1and / or an off-rate constant (koff) of about 1.3 x 10^-3 s-1. In this context, the on-rate constant (kon) values and / or the off-rate constant (koff) values are preferably determined using an SPR Biacore measurement (preferably on samples comprising purified sdAbs). Generally, the lower the KD, the higher the affinity of the corresponding sdAb, meaning the sdAb is capable of detecting a lower limit of CRP concentrations in a biological fluid. This is particularly useful in cases where a very low concentration of analyte e.g. IL6 is present in such a biological fluid. In contrast, CRP is highly concentrated in e.g. human samples, thus, low KD(high affinity) may be less preferred given that in a biosensor setting the biosensor comprising the sdAb with a very low KDwill saturate faster. Accordingly the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising a dissociation constant (KD) of about or less than about 1 x 10^-8 M. Accordingly, the upper limit is about 1 x 10^-8 M, preferably 9.9 x 10^-9 M, more preferably 9.8 x 10^-9 M, even more preferably 9.7 x 10^-9 M, even more preferably 9.69 x 10^-9 M, even more preferably 9.68 x 10^-9 M, even more preferably 9.67 x 10^-9 M, even more preferably 9.66 x 10^-9 M, even more preferably 9.65 x 10^-9 M, even more preferably 9.64 x 10^-9 M, even more preferably 9.63 x 10^-9 M, most preferred about 9.62 x 10^-9 M. The lower limit of the dissociation constant (KD) of the herein provided anti-CRP sdAbs is not particularly limited. Nonetheless, the dissociation constant (KD) of the herein provided anti-CRP sdAbs may comprise a lower limit of about 1 x 10^-16 M, preferably 2 x 10^-16 M, more preferably 3 x 10^-16 M, even more preferably 4 x 10^-16 M, even more preferably 5 x 10^-16 M, even more preferably 6 x 10^-16 M, even more preferably 7 x 10^-16 M, even more preferably 8 x 10^- 16 M, even more preferably 9 x 10^-16 M, even more preferably 1 x 10^-15 M, most preferably 1.8 x 10^-15 M. Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise an dissociation constant (KD) of about 1 x 10^-9 M – 1 x 10^-8 M. In this context, the off-rate constant (koff) values are preferably determined using an SPR Biacore measurement (preferably on samples comprising purified sdAbs). Accordingly, the present invention provides for an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about or more than about 2.1 x 10^5 s- an off-rate constant (koff) of about 2.5 x 10^-9 s-1– 2 x 10^-1 s-1, and / or a dissociation constant (KD) of about less than about 1 x 10^-8 M, preferably wherein said sdAb is capable of detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, preferably wherein kon, koff, and KDvalues are obtained by a SPR Biacore binding kinetic measurement (preferably on samples comprising purified sdAbs). In the context of the present invention, the herein provided anti-CRP sdAbs may be particularly useful in diagnostic applications or in monitoring of CRP levels. Such diagnostic applications or monitoring may be in vivo and / or in vitro and are not particularly limited. They may include continuous monitoring of CRP concentrations, may rely on dilution, may include a forced release mechanism (e.g. via heat, light / optogenetics, vibration, redox potential or pH), and / or a multisensory chip. All of the herein provided sdAbs may be suitable for any of the above listed applications. Accordingly, the present invention provides for anti-CRP sdAbs that are, inter alia, useful in in vitro or in vivo diagnostic applications or continuous monitoring of CRP levels e.g. when being comprised in a biosensor which can be used either in vitro or in vivo, i.e. being partially or fully implanted into a subject. Such anti-CRP sdAbs may be any of the herein provided sdAbs. Preferably, the anti-CRP sdAbs (that are particularly useful in in vitro or in vivo diagnostic applications or applications monitoring CRP levels such as, for example in vitro or in vivo biosensors employing such sdAbs in the continuous monitoring / continuous detection / continuous quantification of CRP concentrations) comprise an on-rate constant (kon) of about 2 x 10^5 s-1M-1– 1 x 10^6 s-1M-1, more preferably of about 3 x 10^5 s-1M-1– 9 x 10^5 s-1M-1, even more preferably of about 3.5 x 10^5 s-1M-1– 8.5 x 10^5 s-1M-1, even more preferably of about 3.8 x 10^5 s-1M-1– 8 x 10^5 s-1M-1. In this context, the on-rate constant (kon) values are preferably determined using a SPR Biacore measurement (preferably on samples comprising purified sdAbs). As is further detailed in the enclosed examples, anti-CRP sdAbs SCR-3E4, SCR-2D1, and SCR-3G7 are particularly useful for in vitro or in vivo diagnostic applications (such as in vivo biosensors). In this context SCR-3E4 and SCR-2D1 may be especially useful as they cover a surprisingly broad inflammation range, comprise a surprisingly high affinity towards CRP, (these advantages are further detailed in Table 13). Anti-CRP sdAbs SCR-2D2, SCR-3H6, SCR-3A5, SCR-2B4, SCR-3H1, SCR-2B4, and SCR- 3A4 may be particularly useful in diagnostic applications that include dilution and / or a forced release mechanism (e.g. via heat, light / optogenetics, vibration, redox potential or pH). Sample dilution allows the antigen concentration within a sample to be aligned with the available kon / koff / KD characteristics of the sdAbs such that continuous monitoring / continuous detection / continuous quantification of CRP concentrations can be achieved using the herein described thermodynamic equilibrium model. Dilution would reduce the slope of the reaction rate (decrease ^^0in Equation 6) and allow to measure a higher number of datapoints to extract ^^0. Alternatively, serial dilution could be used to reduce the input concentration and reach a linear binding regime between CRP and the sdAbs. The optimal dilution factor will depend on the kinetic rate of the sdAbs used as target molecule and the extent of the targeted CRP concentration range. A forced release mechanism (alone or in combination with dilution) such as by an optogenetic release mechanism, increasing temperature, inducing vibration, pH modifications, or changing the redox potential can further allow for continuous monitoring / continuous detection / continuous quantification of CRP concentrations. Combining multi- sensor chips with those approaches could further increase the inflammation ranges to be monitored (i.e. by using different dilutions on separate chips and / or release mechanisms and / or different sdAbs within the same biosensor). In the context of the present invention, the herein provided anti-CRP sdAbs may also be useful in therapeutic applications, which may include the treatment and / or prevention of CRP- associated diseases and / or diseases and / or conditions that are associated with elevated CRP- concentrations (for example in a biological fluid, such as the anti-CRP sdAbs for use in the treatment of a disease associated with an inflammation as provided herein or the corresponding method of treatment as provided herein. Preferred sdAbs useful in one or more of such therapeutic applications may, inter alia, be found in Table 13. Anti-CRP sdAbs SCR-3E5, SCR- 3B7, SCR-3G7, SCR-2D2, SCR-3H6, SCR-3A5, SCR-2B4, SCR-3H1, SCR-2B4, and SCR- 3A4 may be particularly useful in such therapeutic applications given their sub-nanomolar affinity. Anti-CRP sdAbs SCR-2D2, SCR-3H6, SCR-3A5, SCR-2B4, SCR-3H1, SCR-2B4, and SCR-3A4 may be preferred for the herein provided therapeutic applications given their sub- nanomolar affinity. As is detailed in the herein provided non-limiting examples instead of determining or quantifying the binding affinities (such as kon, koff, and KDvalues) using SPR Biacore measurements (as can illustratively be seen in Table 10), such values can also be determined by other means, such as by Octet BLI kinetic measurements (as can, inter alia, illustratively be seen in Table 8). Accordingly, in the context of the present invention an anti-C-reactive protein (CRP) single- domain antibody (sdAb) can comprise an on-rate constant (kon) of about or less than about 1.9 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 1 x 10^-5 s-1– 7 x 10^-3 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs) Accordingly, the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising an on-rate constant (kon) about or less than about 1.9 x 10^5 s-1M-1. Preferably the upper limit is about or less than about 1.9 x 10^5 s-1M-1, more preferably 1.8 x 10^5 s-1M-1, even more preferably 1.7 x 10^5 s-1M-1, even more preferably 1.6 x 10^5 s-1M-1, even more preferably 1.5 x 10^5 s-1M-1, even more preferably 1.4 x 10^5 s-1M-1, even more preferably 1.3 x 10^5 s-1M-1(specifically 1.30 x 10^5 s-1M-1). It may also be preferred herein that the upper limit is about or less than about 1.2 x 10^5 s-1M-1, preferably 1.1 x 10^5 s-1M-1(specifically 1.0 x 10^5 s-1M-1). In this context, the lower limit of the on-rate constant (kon) of the herein provided anti-CRP sdAbs is not particularly limited. Nonetheless, the on-rate constant (kon) of the herein provided anti-CRP sdAbs may comprise a lower limit of about 1 x 10^3 s-1M-1, preferably 2 x 10^3 s-1M-1, more preferably 3 x 10^3 s-1M-1, even more preferably 4 x 10^3 s-1M-1, even more preferably 5 x 10^3 s-1M-1, even more preferably 6 x 10^3 s-1M-1, even more preferably 7 x 10^3 s-1M-1, even more preferably 8 x 10^3 s-1M-1, even more preferably 9 x 10^3 s-1M-1, even more preferably 1 x 10^4 s-1M-1, even more preferably 2 x 10^4 s-1M-1, even more preferably 3 x 10^4 s-1M-1, most preferably 4 x 10^4 s-1M-1(specifically about 4.1 x 10^4 s-1M-1). Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise an on-rate constant (kon) of about 4 x 10^4 s-1M-1– 1.9 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 1 x 10^-5 s-1– 7 x 10^-3 s-1, particularly wherein the values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs), however any other herein above (or below) defined upper and / or lower limit is also envisaged herein. In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise an on-rate constant (kon) of about or more than about 2 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 1 x 10^-5 s-1– 7 x 10^-3 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs) Accordingly, the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising an on-rate constant (kon) about or more than about 2 x 10^5 s-1M-1. Preferably the lower limit is about or more than about 2 x 10^5 s-1M-1, more preferably 2.1 x 10^5 s-1M-1(specifically 2.2 x 10^5 s-1M-1). In this context, the upper limit of the on-rate constant (kon) of the herein provided anti-CRP sdAbs is not particularly limited. Nonetheless, the on-rate constant (kon) of the herein provided anti-CRP sdAbs may comprise a upper limit of about 9 x 10^6 s-1M-1, preferably 8 x 10^6 s-1M-1, more preferably 7 x 10^6 s-1M-1, even more preferably 6 x 10^6 s-1M-1, even more preferably 5 x 10^6 s-1M-1, even more preferably 4 x 10^6 s-1M-1, even more preferably 3 x 10^6 s-1M-1, even more preferably 2 x 10^6 s-1M-1, even more preferably 1 x 10^6 s-1M-1, even more preferably 9 x 10^5 s-1M-1, even more preferably 8 x 10^5 s-1M-1, even more preferably 7 x 10^5 s-1M-1, even more preferably 6 x 10^5 s-1M-1, even more preferably 5 x 10^5 s-1M-1, most preferably 4 x 10^5 s-1M-1(specifically about 3.8 x 10^5 s-1M-1). Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise an on-rate constant (kon) of about 2 x 10^5 s-1M-1– 4 x 10^5 s- and / or an off-rate constant (koff) of about 1 x 10^-5 s-1– 7 x 10^-3 s-1, particularly wherein the values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs), however any other herein above (or below) defined upper and / or lower limit is also envisaged herein. In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise an off-rate constant (koff) of about or less than about 2 x 10^-3 s-1and / or an on-rate constant (kon) of about 4 x 10^4 preferably wherein said values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs) Accordingly, the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising an off-rate constant (koff) about or less than about 2 x 10^-3 s-1. Preferably the upper limit is about or less than about 2 x 10^-3 s-1, more preferably 1 x 10^-3 s-1, even more preferably 9 x 10^-4 s-1, even more preferably 8 x 10^-4 s-1, even more preferably 7 x 10^-4 s-1(specifically 6,8 x 10^-4 s-1). In this context, the lower limit of the off-rate constant (koff) of the herein provided anti-CRP sdAbs is not particularly limited. Nonetheless, the off-rate constant (koff) of the herein provided anti-CRP sdAbs may comprise a lower limit of about 1 x 10^-6 s-1, preferably 2 x 10^-6 s-1, more preferably 3 x 10^-6 s-1, even more preferably 4 x 10^-6 s-1, even more preferably 5 x 10^-6 s-1, even more preferably 6 x 10^-6 s-1, even more preferably 7 x 10^-6 s-1, even more preferably 8 x 10^-6 s-1, even more preferably 9 x 10^-6 s-1, even more preferably 1 x 10^-5 s-1, most preferably 2 x 10^-5 s-1(specifically about 2 x 10^-5 s-1). Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise an off-rate constant (koff) of 2 x 10^-7 s-1– 2 x 10^-3 s-1and / or an on- rate constant (kon) of about 4 x 10^4 particularly wherein the values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs), however any other herein above (or below) defined upper and / or lower limit is also envisaged herein. In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise an off-rate constant (koff) of about or more than about 3 x 10^-3 s-1and / or an on-rate constant (kon) of about 4 x 10^4 preferably wherein said values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs) Accordingly, the present invention relates to an anti-C-reactive protein (CRP) single-domain antibody (sdAb) preferably comprising an off-rate constant (koff) about or more than about 3 x 10^-3 s-1. Preferably the lower limit is about or less than about 3 x 10^-3 s-1, more preferably 4 x 10^-3 s-1, most preferably 5 x 10^-3 s-1(specifically 5,8 x 10^-3 s-1). In this context, the upper limit of the off-rate constant (koff) of the herein provided anti-CRP sdAbs is not particularly limited. Nonetheless, the off-rate constant (koff) of the herein provided anti-CRP sdAbs may comprise an upper limit of about 9 x 10^-2 s-1, preferably 8 x 10^-2 s-1, more preferably 7 x 10^-2 s-1, even more preferably 6 x 10^-2 s-1, even more preferably 5 x 10^-2 s-1, even more preferably 4 x 10^-2 s-1, even more preferably 3 x 10^-2 s-1, even more preferably 2 x 10^-2 s-1, even more preferably 1 x 10^-2 s-1, even more preferably 9 x 10^-3 s-1, even more preferably 8 x 10^-3 s-1, most preferably 7 x 10^-3 s-1(specifically about 6.9 x 10^-3 s-1). Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise an off-rate constant (koff) of 3 x 10^-3 – 7 x 10^-3 s-1s-1and / or an on-rate constant (kon) of about 4 x 10^4 particularly wherein the values are obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs), however any other herein above (or below) defined upper and / or lower limit is also envisaged herein. In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise a dissociation constant (KD) about or less than about 1.2 x 10^-8 M, preferably wherein said value is obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs) Preferably the upper limit is about or less than about 1.2 x 10^-8 M, more preferably 1.1 x 10^- 8 M, even more preferably 1 x 10^-8 M, even more preferably 9 x 10^-9 M, even more preferably 8 x 10^-9 M, even more preferably 7 x 10^-9 M, even more preferably 6 x 10^-9 M (specifically 5.1 x 10^-9 M). In this context, the lower limit of the dissociation constant (KD) of the herein provided anti- CRP sdAbs is not particularly limited. Nonetheless, the dissociation constant (KD) of the herein provided anti-CRP sdAbs may comprise a lower limit of about 5 x 10^-12 M, preferably 6 x 10^-12 M, more preferably 7 x 10^-12 M, even more preferably 8 x 10^-12 M, even more preferably 9 x 10^-12 M, even more preferably 1 x 10^-11 M, even more preferably 2 x 10^-11 M, even more preferably 3 x 10^- 11 M, even more preferably 4 x 10^-11 M, most preferably 5 x 10^-11 M (specifically about 5.8 x 10^-11 M). Accordingly, an anti-CRP sdAb in the sense of the present invention can comprise a dissociation constant (KD) about 5 x 10^-11 M – 1.2 x 10^-8 M, preferably wherein said value is obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs), however any other herein above (or below) defined upper and / or lower limit is also envisaged herein. In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise a dissociation constant (KD) about 1.4 x 10^-8 M – 5 x 10^-8 M, preferably about 1.5 x 10^-8 M – 4 x 10^-8 M, more preferably about 1.6 x 10^-8 M – 3 x 10^-8 M, even more preferably about 1.7 x 10^-8 M – 2 x 10^-8 M, most preferably about 1.7 x 10^-8 M – 1.9 x 10^-8 M, preferably wherein said value is obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs). In the context of the present invention an anti-C-reactive protein (CRP) single-domain antibody (sdAb) can comprise a dissociation constant (KD) about 5.2 x 10^-8 M – 1 x 10^-7 M, preferably about 5.3 x 10^-8 M – 9 x 10^-8 M, more preferably 5.4 x 10^-8 M – 8 x 10^-8 M, even more preferably about 5.5 x 10^-8 M – 7 x 10^-8 M, most preferably about 5.5 x 10^-8 M – 6.5 x 10^-8 M, preferably wherein said value is obtained by an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs). In particular, the present invention provides for anti-CRP sdAb SCR-3E4 (or variants thereof), comprising an on-rate constant (kon) of about 4.1 x 10^4 s-1M-1and / or an off-rate constant (koff) of about 6.8 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3G7 (or variants thereof), comprising an on-rate constant (kon) of about 1.0 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 6.8 x 10^-3 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-2D1 (or variants thereof), comprising an on-rate constant (kon) of about 6.4 x 10^4 s-1M-1and / or an off-rate constant (koff) of about 3.3 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-1A1 (or variants thereof), comprising an on-rate constant (kon) of about 1.3 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 6.9 x 10^-3 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3B7 (or variants thereof), comprising an on-rate constant (kon) of about 3.0 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 5.9 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-2D2 (or variants thereof), comprising an on-rate constant (kon) of about 3.8 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 1.3 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3E5 (or variants thereof), comprising an on-rate constant (kon) of about 2.2 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 3.0 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-2B4 (or variants thereof), comprising an on-rate constant (kon) of about 2.7 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 4.0 x 10^-4 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3H1 (or variants thereof), comprising an on-rate constant (kon) of about 3.0 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 8.1 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3H6 (or variants thereof), comprising an on-rate constant (kon) of about 3.5 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 2.0 x 10^-5 s-1. In particular, the present invention provides for anti-CRP sdAb SCR-3A4 (or variants thereof), comprising an on-rate constant (kon) of about 3.1 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 5.8 x 10^-3 s-1. In this context, the on-rate constant (kon) values and / or the off-rate constant (koff) values are preferably determined using an Octet BLI kinetic measurement (preferably on samples comprising purified sdAbs). In particular, the present invention provides for anti-CRP sdAb SCR-3A5 (or variants thereof), comprising an on-rate constant (kon) of about 1.3 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 2.2 x 10^-1 s-1, preferably wherein the on-rate constant (kon) values and / or the off-rate constant (koff) values are preferably determined using an Octet BLI kinetic measurement (preferably on samples comprising non-purified or crude sdAbs). It is understood that the anti-C-reactive protein (CRP) single-domain antibody (sdAb) of the invention can comprise any of the above disclosed on-rate constant (kon) and / or any of the above disclosed off-rate constant (koff). Any combinations of the disclosed on-rate constant (kon) and off-rate constant (koff) are envisaged. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about or more than about 2.1 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 3 x 10^- 9 s-1– 2 x 10^-2 s-1, preferably wherein said values are obtained by a SPR Biacore measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about or more than about 3.80 x 10^5 s-1M-1and / or an off-rate constant (koff) of about 3.2 x 10^-9 s-1– 1.3 x 10^-2 s-1, preferably wherein said values are obtained by a SPR Biacore kinetic measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about 2.1 x 10^5 s-1M-1– 3 x 10^7 s-1M-1and / or an off-rate constant (koff) of about 3 x 10^- 9 s-1– 2 x 10^-2 s-1, preferably wherein said values are obtained by a SPR Biacore measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.7 x 10^7 s-1M-1and / or an off-rate constant (koff) of about 3.2 x 10^-9 s-1– 1.3 x 10^-2 s-1, preferably wherein said values are obtained by a SPR Biacore kinetic measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about 3 x 10^4 s-1M-1– 5 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 2 x 10^-4 s-1– 3 x 10^-1 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about 3.3 x 10^4 s-1M-1– 4.6 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 2.4 x 10^-4 s-1– 2.2 x 10^-1 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about 3 x 10^5 s-1M-1– 5 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 3 x 10^-4 s-1– 3 x 10^-1 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement. In the sense of the present invention, an anti-CRP sdAb can comprise an on-rate constant (kon) of about 3.9 x 10^5 s-1M-1– 4.6 x 10^6 s-1M-1and / or an off-rate constant (koff) of about 3.7 x 10^-4 s-1– 2.2 x 10^-1 s-1, preferably wherein said values are obtained by an Octet BLI kinetic measurement. In the sense of the present invention, an anti-CRP sdAb can comprise a konof about 3.30 x 10^4 – 1.70 x 10^7 and a koffof about 3.20 x 10^-9 – 2.20 x 10^-1. An anti-CRP sdAb can comprise a konof about 3.80 x 10^5 – 1.70 x 10^7 and koffof about 3.20 x 10^-9 – 1.30 x 10^-2. An anti- CRP sdAb can comprise a konof about 3.30 x 10^4 – 4.60 x 10^6 and koffof about 2.60 x 10^- 4 – 2.20 x 10^-1. An anti-CRP sdAb can comprise a konof about 4.10 x 10^4 – 3.80 x 10^5 and koffof about 2.00 x 10^-5 – 6.90 x 10^-3. An anti-CRP sdAb can have a konof about 3.80 x 10^5 – 1.70 x 10^7 and a koffof about 3.20 x 10^-9 – 1.30 x 10^-2, wherein the values are obtained by a SPR Biacore binding kinetic measurement. An anti-CRP sdAb can have a konof about 3.80 x 10^5 – 1.70 x 10^7 and a koffof about 3.20 x 10^-9 – 1.30 x 10^-2 and optionally a KDof about 1.00 x 10^-2 – 9.62, wherein the values are obtained by a SPR Biacore binding kinetic measurement. An anti-CRP sdAb can comprise a konof about 3.30 x 10^4 – 4.60 x 10^6 and a koffof about 2.60 x 10^-4 – 2.20 x 10^-1, wherein the values are obtained by an Octet BLI binding kinetic measurement. An anti-CRP sdAb can comprise a konof about 3.30 x 10^4 – 4.60 x 10^6 and a koffof about 2.60 x 10^-4 – 2.20 x 10^-1, and optionally a KDof about 1.50 x 10^-10 M – 1.80 x 10^-7 M, wherein the values are obtained by an Octet BLI binding kinetic measurement. An anti-CRP sdAb can comprise a konof about 4.10 x 10^4 – 3.80 x 10^5 and a koffof about 2.00 x 10^-5 – 6.90 x 10^-3, wherein the values are obtained by an Octet BLI binding kinetic measurement. An anti-CRP sdAb can comprise a konof about 4.10 x 10^4 – 3.80 x 10^5 and a koffof about 2.00 x 10^-5 – 6.90 x 10^-3, and optionally a KDof about 5.80 x 10^-11 M – 6.50 x 10^-8 M, wherein the values are obtained by an Octet BLI binding kinetic measurement. The konand koffvalues of a sdAb of the present invention can vary depending on the sdAb, the method of measurement and the measurement setup used. Accordingly, the skilled person is aware that a sdAb of the present invention may not embody strict konand koffvalues, but these may be in a range defined by the above parameters. Accordingly, it is possible to define a certain range of a konand koffvalue by repeating measurements and forming a standard deviation (SD). For example, a SD can be based on repeated measurements, deviations reported in the prior art, and / or minimum and maximum values obtained for SDs from repeated measurements and SDs reported in the prior art. Different means to arrive at standard deviations for the sdAbs of the present application are described in detail in the appended examples. Accordingly, the invention provides in one aspect an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 3.53 x 10^5 – 1.58 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 1.34 x 10^-7 – 1.85 x 10^-2 and optionally a KDof about 1.00 x 10^-2 – 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89. Terms like “on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 3.53 x 10^5 – 1.58 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 1.34 x 10^-7 – 1.85 x 10^-2” as disclosed herein are to be understood to relate to “on-rate constant (kon) of about between (from) 3.80 x 10^5 to 1.70 x 10^7 ± 3.53 x 10^5 – 1.58 x 10^7 (wherein the “± 3.53 x 10^5 – 1.58 x 10^7” is the range of the SD of “between (from) 3.53 x 10^5 – 1.58 x 10^7” associated with the indicated range of the on-rate constant (kon)) and an off-rate constant (koff) of between (from) 3.20 x 10^-9 – 1.30 x 10^-2 ± 1.34 x 10^-7 – 1.85 x 10^-2 (wherein the “ ± 1.34 x 10^-7 – 1.85 x 10^-2” is the range of the SD of “between (from) 1.34 x 10^-7 to 1.85 x 10^-2” associated with the indicated range of the off-rate constant (koff)”. This explanation applies to all similar terms disclosed herein. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 3.53 x 10^5 – 1.58 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 4.56 x 10^-9 – 1.85 x 10^-2 and optionally a KDof about 1.00 x 10^-2 – 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 9.06 x 10^2 – 3.00 x 10^5 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 1.34 x 10^-7 – 8.82 x 10^-5 and optionally a KD of about 1.00 x 10^-2 – 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.30 x 10^6 ± 1.21 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-2 ± 1.85 x 10^-2 and optionally a KDof about 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 1. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.30 x 10^6 ± 9.31 x 10^3 and an off-rate constant (koff) of about 1.30 x 10^-2 ± 8.82 x 10^-5 and optionally a KDof about 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 1. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 1.58 x 10^6 and an off-rate constant (koff) of about 1.70 x 10^-4 ± 2.42 x 10^-4 and optionally a KDof about 0.10, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 9. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 5.00 x 10^3 and an off-rate constant (koff) of about 1.70 x 10^-4 ± 2.20 x 10^-6 and optionally a KDof about 0.10, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 9. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 8.00 x 10^5 ± 7.43 x 10^5 and an off-rate constant (koff) of about 3.00 x 10^-4 ± 4.28 x 10^-4 and optionally a KDof about 0.38, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 17. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 8.00 x 10^5 ± 1.26 x 10^3 and an off-rate constant (koff) of about 3.00 x 10^-4 ± 1.20 x 10^-6 and optionally a KDof about 0.38, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 17. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.60 x 10^6 ± 1.49 x 10^6 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 2.85 x 10^-5 and optionally a KDof about 0.01, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 25. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.60 x 10^6 ± 3.80 x 10^3 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 1.79 x 10^-6 and optionally a KDof about 0.01, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 25. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.70 x 10^6 ± 2.51 x 10^6 and an off-rate constant (koff) of about 1.90 x 10^-3 ± 2.71 x 10^-3 and optionally a KDof about 0.70, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 33. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.70 x 10^6 ± 4.47 x 10^4 and an off-rate constant (koff) of about 1.90 x 10^-3 ± 2.91 x 10^-5 and optionally a KDof about 0.70, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 33. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^7 ± 1.58 x 10^7 and an off-rate constant (koff) of about 1.30 x 10^-3 ± 1.85 x 10^-3 and optionally a KDof about 0.08, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 41. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^7 ± 3.00 x 10^5 and an off-rate constant (koff) of about 1.30 x 10^-3 ± 2.00 x 10^-5 and optionally a KDof about 0.08, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 41. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.50 x 10^6 ± 1.39 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-7 ± 1.88 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.50 x 10^6 ± 1.39 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-7 ± 1.85 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.50 x 10^6 ± 3.80 x 10^3 and an off-rate constant (koff) of about 1.30 x 10^-7 ± 1.88 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 3.53 x 10^5 and an off-rate constant (koff) of about 6.20 x 10^-5 ± 8.84 x 10^-5 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 57. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 9.06 x 10^2 and an off-rate constant (koff) of about 6.20 x 10^-5 ± 2.28 x 10^-6 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 57. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 1.58 x 10^6 and an off-rate constant (koff) of about 3.20 x 10^-9 ± 1.34 x 10^-7 and optionally a KDof about 1.80 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 1.58 x 10^6 and an off-rate constant (koff) of about 3.20 x 10^-9 ± 4.56 x 10^-9 and optionally a KDof about 1.80 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 2.46 x 10^3 and an off-rate constant (koff) of about 3.20 x 10^-9 ± 1.34 x 10^-7 and optionally a KDof about 1.80 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 6.00 x 10^5 ± 5.57 x 10^5 and an off-rate constant (koff) of about 9.80 x 10^-5 ± 1.40 x 10^-4 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 73. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 6.00 x 10^5 ± 6.24 x 10^3 and an off-rate constant (koff) of about 9.80 x 10^-5 ± 1.11 x 10^-6 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 73. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.10 x 10^6 ± 1.95 x 10^6 and an off-rate constant (koff) of about 2.50 x 10^-4 ± 3.57 x 10^-4 and optionally a KDof about 0.12, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 81. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.10 x 10^6 ± 4.47 x 10^3 and an off-rate constant (koff) of about 2.50 x 10^-4 ± 1.86 x 10^-6 and optionally a KDof about 0.12, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 81. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.40 x 10^6 ± 2.23 x 10^6 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 1.16 x 10^-4 and optionally a KDof about 0.03, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 89. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.40 x 10^6 ± 4.90 x 10^3 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 2.69 x 10^-7 and optionally a KDof about 0.03, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 89. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 3.53 x 10^5 – 1.58 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 1.34 x 10^-7 – 1.85 x 10^-2 and optionally a KDof about 1.00 x 10^-2 – 9.62, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 3.53 x 10^5 – 1.58 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 4.56 x 10^-9 – 1.85 x 10^-2 and optionally a KDof about 1.00 x 10^-2 – 9.62, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 ± 9.06 x 10^2 – 3.00 x 10^5 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2 ± 1.34 x 10^-7 – 8.82 x 10^-5 and optionally a KDof about 1.00 x 10^-2 – 9.62, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.30 x 10^6 ± 1.21 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-2 ± 1.85 x 10^-2 and optionally a KDof about 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.30 x 10^6 ± 9.31 x 10^3 and an off-rate constant (koff) of about 1.30 x 10^-2 ± 8.82 x 10^-5 and optionally a KDof about 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 1.58 x 10^6 and an off-rate constant (koff) of about 1.70 x 10^-4 ± 2.42 x 10^-4 and optionally a KDof about 0.10, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 5.00 x 10^3 and an off-rate constant (koff) of about 1.70 x 10^-4 ± 2.20 x 10^-6 and optionally a KDof about 0.10, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 8.00 x 10^5 ± 7.43 x 10^5 and an off-rate constant (koff) of about 3.00 x 10^-4 ± 4.28 x 10^-4 and optionally a KDof about 0.38, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 8.00 x 10^5 ± 1.26 x 10^3 and an off-rate constant (koff) of about 3.00 x 10^-4 ± 1.20 x 10^-6 and optionally a KDof about 0.38, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.60 x 10^6 ± 1.49 x 10^6 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 2.85 x 10^-5 and optionally a KDof about 0.01, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.60 x 10^6 ± 3.80 x 10^3 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 1.79 x 10^-6 and optionally a KDof about 0.01, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.70 x 10^6 ± 2.51 x 10^6 and an off-rate constant (koff) of about 1.90 x 10^-3 ± 2.71 x 10^-3 and optionally a KDof about 0.70, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.70 x 10^6 ± 4.47 x 10^4 and an off-rate constant (koff) of about 1.90 x 10^-3 ± 2.91 x 10^-5 and optionally a KDof about 0.70, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 43 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 45 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 47 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^7 ± 1.58 x 10^7 and an off-rate constant (koff) of about 1.30 x 10^-3 ± 1.85 x 10^-3 and optionally a KDof about 0.08, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 43 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 45 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 47 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^7 ± 3.00 x 10^5 and an off-rate constant (koff) of about 1.30 x 10^-3 ± 2.00 x 10^-5 and optionally a KDof about 0.08, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.50 x 10^6 ± 1.39 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-7 ± 1.88 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.50 x 10^6 ± 1.39 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-7 ± 1.85 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.50 x 10^6 ± 3.80 x 10^3 and an off-rate constant (koff) of about 1.30 x 10^-7 ± 1.88 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 59 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 61 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 63or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 3.53 x 10^5 and an off-rate constant (koff) of about 6.20 x 10^-5 ± 8.84 x 10^-5 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 59 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 61 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 63 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 9.06 x 10^2 and an off-rate constant (koff) of about 6.20 x 10^-5 ± 2.28 x 10^-6 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 1.58 x 10^6 and an off-rate constant (koff) of about 3.20 x 10^-9 ± 1.34 x 10^-7 and optionally a KDof about 1.80 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 1.58 x 10^6 and an off-rate constant (koff) of about 3.20 x 10^-9 ± 4.56 x 10^-9 and optionally a KDof about 1.80 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.70 x 10^6 ± 2.46 x 10^3 and an off-rate constant (koff) of about 3.20 x 10^-9 ± 1.34 x 10^-7 and optionally a KDof about 1.80 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 6.00 x 10^5 ± 5.57 x 10^5 and an off-rate constant (koff) of about 9.80 x 10^-5 ± 1.40 x 10^-4 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 6.00 x 10^5 ± 6.24 x 10^3 and an off-rate constant (koff) of about 9.80 x 10^-5 ± 1.11 x 10^-6 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.10 x 10^6 ± 1.95 x 10^6 and an off-rate constant (koff) of about 2.50 x 10^-4 ± 3.57 x 10^-4 and optionally a KDof about 0.12, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.10 x 10^6 ± 4.47 x 10^3 and an off-rate constant (koff) of about 2.50 x 10^-4 ± 1.86 x 10^-6 and optionally a KDof about 0.12, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.40 x 10^6 ± 2.23 x 10^6 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 1.16 x 10^-4 and optionally a KDof about 0.03, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.40 x 10^6 ± 4.90 x 10^3 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 2.69 x 10^-7 and optionally a KDof about 0.03, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement. Accordingly, the invention provides in one aspect an anti-CRP sdAb comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 ± 3.81 x 10^4 – 3.53 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3 ± 2.85 x 10^-5 – 9.84 x 10^-3 and optionally a KDof about 5.80 x 10^-11 M – 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 49, 57, 65, 73, 81, 89. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 ± 3.31 x 10^2 – 1.48 x 10^4 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3 ± 1.41 x 10^-6 – 8.61 x 10^-5 and optionally a KDof about 5.80 x 10^-11 M – 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 49, 57, 65, 73, 81, 89. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.30 x 10^5 ± 1.21 x 10^5 and an off-rate constant (koff) of about 6.90 x 10^-3 ± 9.84 x 10^-3 and optionally a KDof about 5.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 1. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.30 x 10^5 ± 3.02 x 10^3 and an off-rate constant (koff) of about 6.90 x 10^-3 ± 4.29 x 10^-5 and optionally a KDof about 5.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 1. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.70 x 10^5 ± 2.51 x 10^5 and an off-rate constant (koff) of about 4.00 x 10^-4 ± 5.70 x 10^-4 and optionally a KDof about 1.50 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 9. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.70 x 10^5 ± 1.80 x 10^3 and an off-rate constant (koff) of about 4.00 x 10^-4 ± 3.44 x 10^-6 and optionally a KDof about 1.50 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 9. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 6.40 x 10^4 ± 5.94 x 10^4 and an off-rate constant (koff) of about 3.30 x 10^-4 ± 4.71 x 10^-4 and optionally a KDof about 5.10 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 17. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 6.40 x 10^4 ± 4.22 x 10^2 and an off-rate constant (koff) of about 3.30 x 10^-4 ± 2.48 x 10^-6 and optionally a KDof about 5.10 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 17. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 3.53 x 10^5 and an off-rate constant (koff) of about 1.30 x 10^-4 ± 1.85 x 10^-4 and optionally a KDof about 3.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 25. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 4.34 x 10^3 and an off-rate constant (koff) of about 1.30 x 10^-4 ± 5.53 x 10^-6 and optionally a KDof about 3.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 25. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.10 x 10^5 ± 2.88 x 10^5 and an off-rate constant (koff) of about 5.80 x 10^-3 ± 8.27 x 10^-3 and optionally a KDof about 1.90 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 33. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.10 x 10^5 ± 1.48 x 10^4 and an off-rate constant (koff) of about 5.80 x 10^-3 ± 8.61 x 10^-5 and optionally a KDof about 1.90 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 33. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 2.79 x 10^5 and an off-rate constant (koff) of about 5.90 x 10^-5 ± 8.41 x 10^-5 and optionally a KDof about 1.90 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 8.37 x 10^2 and an off-rate constant (koff) of about 5.90 x 10^-5 ± 1.41 x 10^-6 and optionally a KDof about 1.90 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 4.10 x 10^4 ± 3.81 x 10^4 and an off-rate constant (koff) of about 6.80 x 10^-4 ± 9.70 x 10^-4 and optionally a KDof about 1.70 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 57. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 4.10 x 10^4 ± 3.31 x 10^2 and an off-rate constant (koff) of about 6.80 x 10^-4 ± 3.27 x 10^-6 and optionally a KDof about 1.70 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 57. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.20 x 10^5 ± 2.04 x 10^5 and an off-rate constant (koff) of about 3.00 x 10^-5 ± 4.28 x 10^-5 and optionally a KDof about 1.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 2.20 x 10^5 ± 1.09 x 10^3 and an off-rate constant (koff) of about 3.00 x 10^-5 ± 2.65 x 10^-6 and optionally a KDof about 1.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.00 x 10^5 ± 9.29 x 10^4 and an off-rate constant (koff) of about 6.80 x 10^-3 ± 9.70 x 10^-3 and optionally a KDof about 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 73. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 1.00 x 10^5 ± 4.84 x 10^3 and an off-rate constant (koff) of about 6.80 x 10^-3 ± 8.57 x 10^-5 and optionally a KDof about 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 73. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 2.79 x 10^5 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 1.16 x 10^-4 and optionally a KDof about 2.70 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 81. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 1.58 x 10^3 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 2.73 x 10^-6 and optionally a KDof about 2.70 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 81. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.50 x 10^5 ± 3.25 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 2.85 x 10^-5 and optionally a KDof about 5.80 x 10^-11 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 89. In some embodiments, the invention provides an anti-CRP sdAb comprising an on-rate constant (kon) of about 3.50 x 10^5 ± 2.36 x 10^3 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 3.39 x 10^-6 and optionally a KDof about 5.80 x 10^-11 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 89. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.30 x 10^4 – 4.60 x 10^6 and an off-rate constant (koff) of about 2.60 x 10^-4 – 2.20 x 10^-1, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 ± 3.81 x 10^4 – 3.53 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3 ± 2.85 x 10^-5 – 9.84 x 10^-3 and optionally a KDof about 5.80 x 10^-11 M – 6.50 x 10^-8 M, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a first complementary determining region (CDR1) or a variant thereof having up to two amino acid substitutions, a second CDR (CDR2) or a variant thereof having up to two amino acid substitutions and a third CDR (CDR3) or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 ± 3.31 x 10^2 – 1.48 x 10^4 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3 ± 1.41 x 10^-6 – 8.61 x 10^-5 and optionally a KDof about 5.80 x 10^-11 M – 6.50 x 10^-8 M, wherein CDR1 comprises any one of SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, wherein CDR2 comprises any one of SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93 and wherein CDR3 comprises any one of SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.30 x 10^5 ± 1.21 x 10^5 and an off-rate constant (koff) of about 6.90 x 10^-3 ± 9.84 x 10^-3 and optionally a KDof about 5.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.30 x 10^5 ± 3.02 x 10^3 and an off-rate constant (koff) of about 6.90 x 10^-3 ± 4.29 x 10^-5 and optionally a KDof about 5.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.70 x 10^5 ± 2.51 x 10^5 and an off-rate constant (koff) of about 4.00 x 10^-4 ± 5.70 x 10^-4 and optionally a KDof about 1.50 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.70 x 10^5 ± 1.80 x 10^3 and an off-rate constant (koff) of about 4.00 x 10^-4 ± 3.44 x 10^-6 and optionally a KDof about 1.50 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 6.40 x 10^4 ± 5.94 x 10^4 and an off-rate constant (koff) of about 3.30 x 10^-4 ± 4.71 x 10^-4 and optionally a KDof about 5.10 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 6.40 x 10^4 ± 4.22 x 10^2 and an off-rate constant (koff) of about 3.30 x 10^-4 ± 2.48 x 10^-6 and optionally a KDof about 5.10 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 3.53 x 10^5 and an off-rate constant (koff) of about 1.30 x 10^-4 ± 1.85 x 10^-4 and optionally a KDof about 3.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.80 x 10^5 ± 4.34 x 10^3 and an off-rate constant (koff) of about 1.30 x 10^-4 ± 5.53 x 10^-6 and optionally a KDof about 3.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.10 x 10^5 ± 2.88 x 10^5 and an off-rate constant (koff) of about 5.80 x 10^-3 ± 8.27 x 10^-3 and optionally a KDof about 1.90 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.10 x 10^5 ± 1.48 x 10^4 and an off-rate constant (koff) of about 5.80 x 10^-3 ± 8.61 x 10^-5 and optionally a KDof about 1.90 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 2.79 x 10^5 and an off-rate constant (koff) of about 5.90 x 10^-5 ± 8.41 x 10^-5 and optionally a KDof about 1.90 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 8.37 x 10^2 and an off-rate constant (koff) of about 5.90 x 10^-5 ± 1.41 x 10^-6 and optionally a KDof about 1.90 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 59 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 61 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 63or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 4.10 x 10^4 ± 3.81 x 10^4 and an off-rate constant (koff) of about 6.80 x 10^-4 ± 9.70 x 10^-4 and optionally a KDof about 1.70 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 59 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 61 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 63 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 4.10 x 10^4 ± 3.31 x 10^2 and an off-rate constant (koff) of about 6.80 x 10^-4 ± 3.27 x 10^-6 and optionally a KDof about 1.70 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.20 x 10^5 ± 2.04 x 10^5 and an off-rate constant (koff) of about 3.00 x 10^-5 ± 4.28 x 10^-5 and optionally a KDof about 1.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.20 x 10^5 ± 1.09 x 10^3 and an off-rate constant (koff) of about 3.00 x 10^-5 ± 2.65 x 10^-6 and optionally a KDof about 1.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.00 x 10^5 ± 9.29 x 10^4 and an off-rate constant (koff) of about 6.80 x 10^-3 ± 9.70 x 10^-3 and optionally a KDof about 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 1.00 x 10^5 ± 4.84 x 10^3 and an off-rate constant (koff) of about 6.80 x 10^-3 ± 8.57 x 10^-5 and optionally a KDof about 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 2.79 x 10^5 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 1.16 x 10^-4 and optionally a KDof about 2.70 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.00 x 10^5 ± 1.58 x 10^3 and an off-rate constant (koff) of about 8.10 x 10^-5 ± 2.73 x 10^-6 and optionally a KDof about 2.70 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 3.50 x 10^5 ± 3.25 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 ± 2.85 x 10^-5 and optionally a KDof about 5.80 x 10^-11 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-CRP sdAb comprising a CDR1 comprising SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprising SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprising SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions, comprising an on-rate constant (kon) of about 2.00 x 10^-5 ± 3.39 x 10^-6 and optionally a KDof about 5.80 x 10^-11 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.30 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-2 and optionally a KDof about 9.62, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 1. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.70 x 10^6 and an off-rate constant (koff) of about 1.70 x 10^-4 and optionally a KDof about 0.10, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 9. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 8.00 x 10^5 and an off-rate constant (koff) of about 3.00 x 10^-4 and optionally a KDof about 0.38, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 17. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.60 x 10^6 and an off-rate constant (koff) of about 2.00 x 10^-5 and optionally a KDof about 0.01, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 25. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 2.70 x 10^6 and an off-rate constant (koff) of about 1.90 x 10^-3 and optionally a KDof about 0.70, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 33. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.70 x 10^7 and an off-rate constant (koff) of about 1.30 x 10^-3 and optionally a KDof about 0.08, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 41. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.50 x 10^6 and an off-rate constant (koff) of about 1.30 x 10^-7 and optionally a KDof about 7.60 x 10^-5, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.80 x 10^5 and an off-rate constant (koff) of about 6.20 x 10^-5 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 57. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.70 x 10^6 and an off-rate constant (koff) of about 3.20 x 10^-9 and optionally a KDof about 1.8 x 10^-6, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 6.00 x 10^5 and an off-rate constant (koff) of about 9.80 x 10^-5 and optionally a KDof about 0.16, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 73. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 2.10 x 10^6 and an off-rate constant (koff) of about 2.50 x 10^-4 and optionally a KDof about 0.12, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 81. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 2.40 x 10^6 and an off-rate constant (koff) of about 8.10 x 10^-5 and optionally a KDof about 0.03, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 89. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 6.20 x 10^5 and an off-rate constant (koff) of about 9.30 x 10^-2 and optionally a KDof about 1.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 1. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 6.20 x 10^5 and an off-rate constant (koff) of about 1.90 x 10^-3 and optionally a KDof about 3.10 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 9. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 4.10 x 10^4 and an off-rate constant (koff) of about 1.20 x 10^-3 and optionally a KDof about 2.90 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 17. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 5.70 x 10^5 and an off-rate constant (koff) of about 5.70 x 10^-4 and optionally a KDof about 1.00 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 25. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.00 x 10^6 and an off-rate constant (koff) of about 8.60 x 10^-3 and optionally a KDof about 8.50 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 33. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.30 x 10^6 and an off-rate constant (koff) of about 2.20 x 10^-1 and optionally a KDof about 1.80 x 10^-7 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 41. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 1.80 x 10^6 and an off-rate constant (koff) of about 3.70 x 10^-4 and optionally a KDof about 2.00 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 49. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 and an off-rate constant (koff) of about 2.60 x 10^-4 and optionally a KDof about 7.80 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 57. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 2.70 x 10^6 and an off-rate constant (koff) of about 3.90 x 10^-4 and optionally a KDof about 1.50 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 65. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.90 x 10^5 and an off-rate constant (koff) of about 2.80 x 10^-3 and optionally a KDof about 7.30 x 10^-9 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 73. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 4.60 x 10^6 and an off-rate constant (koff) of about 1.10 x 10^-3 and optionally a KDof about 2.40 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 81. In some embodiments, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 2.40 x 10^6 and an off-rate constant (koff) of about 4.60 x 10^-4 and optionally a KDof about 1.90 x 10^-10 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in SEQ ID NO: 89. In one aspect, the present invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon), an off-rate constant (koff) and optionally a KDas defined in any one of Tables 6, 7, 10 or 11, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement or an Octet BLI binding kinetic measurement. Accordingly, the present invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 - 1.70 x 10^7 and an off-rate constant (koff) of about 3.2 x 10^-9 - 2.20 x 10^-1. A sdAb comprises framework regions (FRs) and complementary determining regions (CDRs). The FRs are structural components, whereas the CDRs determine the specificity. In general, a sdAb of the present invention consists of four FRs and three CDRs. A sdAb of the present invention can be defined by its CDRs which determine the specificity and the epitope bound. The invention is not particularly limited to sdAb comprising specific CDRs. In particular, the invention provides herein below a detailed description how sdAb having desired konand koffvalues may be obtained. Accordingly, the skilled person is in the position to generate and select further anti-CRP sdAb according to the invention. In particular, the skilled person is in the position to select antibodies having CDRs having desired konand koffvalues according to the present invention. The invention provides exemplary sdAb having CRP specific CDRs and specific konand koffvalues allowing for specific, reversible and therefore continuous association and dissociation with CRP over time. Exemplary sdAb of the present invention can comprise a first CDR, a second CDR and a third CDR, wherein the first CDR is selected from SEQ ID NOs: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, or 91, and wherein the second CDR is selected from SEQ ID NOs: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77, 85, or 93, and wherein the third CDR is selected from SEQ ID NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, or 95. It is envisioned herein, that the CDRs of a sdAb also comprise variants thereof having one or more amino acid modifications. An “amino-acid modification” at a specified position, e.g. of the CDR, refers to the substitution or deletion of the specified residue, or the insertion of at least one amino acid residue adjacent the specified residue. Insertion “adjacent” to a specified residue means insertion within one to two residues thereof. The insertion may be N-terminal or C-terminal to the specified residue. The preferred amino acid modification herein is a substitution. Accordingly, the invention provides CDRs or variants thereof having amino acid substitutions. It may be preferred herein, that said one or more amino acid substitutions do not interfere with the ability of the sdAb to continuously associate and dissociate with CRP over time. A CDR of the present invention may have one or more amino acid substitutions. A CDR of the present invention may have 1-10 amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions. A first CDR of the invention may have 1-2 amino acid substitutions, such as 1 or 2 amino acid substitutions and / or up to 2 amino acid substitutions. A second CDR may have 1-2 amino acid substitutions, such as 1 or 2 amino acid substitutions and / or up to 2 amino acid substitutions. A third CDR may have 1-5 amino acid substitutions, such as 1, 2, 3, 4, or 5 amino acid substitutions and / or up to 5 amino acid substitutions. It is preferred herein, that a sdAb of the present invention comprises a first CDR, a second CDR and a third CDR, wherein, (i) the first CDR comprises SEQ ID NO: 3, the second CDR comprises SEQ ID NO: 5 and the third CDR comprises SEQ ID NO: 7, or (ii) the first CDR comprises SEQ ID NO: 11, the second CDR comprises SEQ ID NO: 13 and the third CDR comprises SEQ ID NO: 15, or (iii) the first CDR comprises SEQ ID NO: 19, the second CDR comprises SEQ ID NO: 21 and the third CDR comprises SEQ ID NO: 23, or (iv) the first CDR comprises SEQ ID NO: 27, the second CDR comprises SEQ ID NO: 29 and the third CDR comprises SEQ ID NO: 31, or (v) the first CDR comprises SEQ ID NO: 35, the second CDR comprises SEQ ID NO: 37 and the third CDR comprises SEQ ID NO: 39, or (vi) the first CDR comprises SEQ ID NO: 43, the second CDR comprises SEQ ID NO: 45 and the third CDR comprises SEQ ID NO: 47, or (vii) the first CDR comprises SEQ ID NO: 51, the second CDR comprises SEQ ID NO: 53 and the third CDR comprises SEQ ID NO: 55, or (viii) the first CDR comprises SEQ ID NO: 59, the second CDR comprises SEQ ID NO: 61 and the third CDR comprises SEQ ID NO: 63, or (ix) the first CDR comprises SEQ ID NO: 67, the second CDR comprises SEQ ID NO: 69 and the third CDR comprises SEQ ID NO: 71, or (x) the first CDR comprises SEQ ID NO: 75, the second CDR comprises SEQ ID NO: 77 and the third CDR comprises SEQ ID NO: 79, or (xi) the first CDR comprises SEQ ID NO: 83, the second CDR comprises SEQ ID NO: 85 and the third CDR comprises SEQ ID NO: 87, or (xii) the first CDR comprises SEQ ID NO: 91, the second CDR comprises SEQ ID NO: 93 and the third CDR comprises SEQ ID NO: 95. In another aspect, it is preferred herein that a sdAb of the present invention comprises a first CDR, a second CDR and a third CDR, wherein, (i) the first CDR comprises SEQ ID NO: 3 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 5 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 7 or a variant thereof having one, two, three, four or five amino acid substitutions, or (ii) the first CDR comprises SEQ ID NO: 11 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 13 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 15 or a variant thereof having one, two, three, four or five amino acid substitutions, or (iii) the first CDR comprises SEQ ID NO: 19 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 21 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 23 or a variant thereof having one, two, three, four or five amino acid substitutions, or (iv) the first CDR comprises SEQ ID NO: 27 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 29 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 31 or a variant thereof having one, two, three, four or five amino acid substitutions, or (v) the first CDR comprises SEQ ID NO: 35 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 37 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 39 or a variant thereof having one, two, three, four or five amino acid substitutions, or (vi) the first CDR comprises SEQ ID NO: 43 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 45 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 47 or a variant thereof having one, two, three, four or five amino acid substitutions, or (vii) the first CDR comprises SEQ ID NO: 51 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 53 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 55 or a variant thereof having one, two, three, four or five amino acid substitutions, or (viii) the first CDR comprises SEQ ID NO: 59 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 61 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 63 or a variant thereof having one, two, three, four or five amino acid substitutions, or (ix) the first CDR comprises SEQ ID NO: 67 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 69 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 71 or a variant thereof having one, two, three, four or five amino acid substitutions, or (x) the first CDR comprises SEQ ID NO: 75 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 77 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 79 or a variant thereof having one, two, three, four or five amino acid substitutions, or (xi) the first CDR comprises SEQ ID NO: 83 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 85 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 87 or a variant thereof having one, two, three, four or five amino acid substitutions, or (xii) the first CDR comprises SEQ ID NO: 91 or a variant thereof having one or two amino acid substitutions, the second CDR comprises SEQ ID NO: 93 or a variant thereof having one or two amino acid substitutions, and the third CDR comprises SEQ ID NO: 95 or a variant thereof having one, two, three, four or five amino acid substitutions. Accordingly, the invention provides in one aspect an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 - 1.70 x 10^7 and an off-rate constant (koff) of about 3.30 x 10^4 - 1.70 x 10^7, comprising a first complementary determining region (CDR1), a second CDR (CDR2) and third CDR (CDR3), wherein: (i) CDR1 comprises SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions; or (ii) CDR1 comprises SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions; or (iii) CDR1 comprises SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions; or (iv) CDR1 comprises SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions; or (v) CDR1 comprises SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions; or (vi) CDR1 comprises SEQ ID NO: 43 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 45 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 47 or a variant thereof having up to five amino acid substitutions; or (vii) CDR1 comprises SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions; or (viii) CDR1 comprises SEQ ID NO: 59 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 61 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 63 or a variant thereof having up to five amino acid substitutions; or (ix) CDR1 comprises SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions; or (x) CDR1 comprises SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions; or (xi) CDR1 comprises SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions; or (xii) CDR1 comprises SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions. As mentioned herein above, a sdAb of the present invention can also comprise structural framework regions (FR). In general, the sdAb of the present invention are not limited to any FRs, rather any FR that results in a functional sdAb according to the present invention may be used. The invention provides herein below a detailed description how feasible FRs can be selected. Accordingly, the skilled person is enabled to select FRs that can be used in the sense of the invention. The invention provides exemplary FRs that can be used with the CDRs described herein to form a sdAb according to the invention. Exemplary FRs can comprise a first FR, a second FR, a third FR and a fourth FR. It may be preferred herein, that a first FR comprises any one of SEQ ID NOs: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, or 90, a second FR comprises any one of SEQ ID NOs: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, or 92, a third FR comprises any one of SEQ ID NOs: 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, or 94 and a fourth FR comprises any one of SEQ ID NOs: 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, or 96. The FRs in a sdAb have structural function. Accordingly, it is envisioned herein, that the FRs of a sdAb also comprise variants thereof having one or more amino acid modifications. The invention provides FRs or variants thereof having amino acid substitutions. It may be preferred herein, that said one or more amino acid substitutions do not interfere with the ability of the sdAb to continuously associate and dissociate with CRP over time. It may further be preferred herein, that said one or more amino acid substitutions do not interfere with the structural integrity of the sdAb. A FR of the present invention may have one or more amino acid substitutions. A FR of the present invention may have 1-10 amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions. A first FR of the invention may have 1-6 amino acid substitutions, such as 1, 2, 3, 4, 5, or 6 amino acid substitutions and / or up to 6 amino acid substitutions. A second CDR may have 1-4 amino acid substitutions, such as 1, 2, 3, or 4 amino acid substitutions and / or up to 4 amino acid substitutions. A third CDR may have 1-10 amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions and / or up to 10 amino acid substitutions. A third CDR may have 1-3 amino acid substitutions, such as 1, 2, or 3 amino acid substitutions and / or up to 3 amino acid substitutions. It is preferred herein, that a sdAb of the present invention comprises a first FR, a second FR, a third FR and a fourth FR, wherein, (i) the first FR comprises SEQ ID NO: 2, the second FR comprises SEQ ID NO: 4, the third FR comprises SEQ ID NO: 6, and the fourth FR comprises SEQ ID NO: 8, or (ii) the first FR comprises SEQ ID NO: 10, the second FR comprises SEQ ID NO: 12, the third FR comprises SEQ ID NO: 14, and the fourth FR comprises SEQ ID NO: 16, or (iii) the first FR comprises SEQ ID NO: 18, the second FR comprises SEQ ID NO: 20, the third FR comprises SEQ ID NO: 22, and the fourth FR comprises SEQ ID NO: 24, or (iv) the first FR comprises SEQ ID NO: 26, the second FR comprises SEQ ID NO: 28, the third FR comprises SEQ ID NO: 30, and the fourth FR comprises SEQ ID NO: 32, or (v) the first FR comprises SEQ ID NO: 34, the second FR comprises SEQ ID NO: 36, the third FR comprises SEQ ID NO: 38, and the fourth FR comprises SEQ ID NO: 40, or (vi) the first FR comprises SEQ ID NO: 42, the second FR comprises SEQ ID NO: 44, the third FR comprises SEQ ID NO: 46, and the fourth FR comprises SEQ ID NO: 48, or (vii) the first FR comprises SEQ ID NO: 50, the second FR comprises SEQ ID NO: 52, the third FR comprises SEQ ID NO: 54, and the fourth FR comprises SEQ ID NO: 56, or (viii) the first FR comprises SEQ ID NO: 58, the second FR comprises SEQ ID NO: 60, the third FR comprises SEQ ID NO: 62, and the fourth FR comprises SEQ ID NO: 64, or (ix) the first FR comprises SEQ ID NO: 66, the second FR comprises SEQ ID NO: 68, the third FR comprises SEQ ID NO: 70, and the fourth FR comprises SEQ ID NO: 72, or (x) the first FR comprises SEQ ID NO: 74, the second FR comprises SEQ ID NO: 76, the third FR comprises SEQ ID NO: 78, and the fourth FR comprises SEQ ID NO: 80, or (xi) the first FR comprises SEQ ID NO: 82, the second FR comprises SEQ ID NO: 84, the third FR comprises SEQ ID NO: 86, and the fourth FR comprises SEQ ID NO: 88, or (xii) the first FR comprises SEQ ID NO: 90, the second FR comprises SEQ ID NO: 92, the third FR comprises SEQ ID NO: 94, and the fourth FR comprises SEQ ID NO: 96. In another aspect, it is preferred herein, that a sdAb of the present invention comprises a first FR, a second FR and a third FR, wherein, (i) the first FR comprises SEQ ID NO: 2 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 4 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 6 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 8 or a variant thereof having one, two, or three amino acid substitutions, or (ii) the first FR comprises SEQ ID NO: 10 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 12 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 14 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 16 or a variant thereof having one, two, or three amino acid substitutions, or (iii) the first FR comprises SEQ ID NO: 18 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 20 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 22 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 24 or a variant thereof having one, two, or three amino acid substitutions, or (iv) the first FR comprises SEQ ID NO: 26 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 28 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 30 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 32 or a variant thereof having one, two, or three amino acid substitutions, or (v) the first FR comprises SEQ ID NO: 34 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 36 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 38 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 40 or a variant thereof having one, two, or three amino acid substitutions, or (vi) the first FR comprises SEQ ID NO: 42 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 44 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 46 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 48 or a variant thereof having one, two, or three amino acid substitutions, or (vii) the first FR comprises SEQ ID NO: 50 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 52 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 54 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 56 or a variant thereof having one, two, or three amino acid substitutions, or (viii) the first FR comprises SEQ ID NO: 58 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 60 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 62 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 64 or a variant thereof having one, two, or three amino acid substitutions, or (ix) the first FR comprises SEQ ID NO: 66 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 68 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 70 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 72 or a variant thereof having one, two, or three amino acid substitutions, or (x) the first FR comprises SEQ ID NO: 74 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 76 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 78 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 80 or a variant thereof having one, two, or three amino acid substitutions, or (xi) the first FR comprises SEQ ID NO: 82 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 84 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 86 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 88 or a variant thereof having one, two, or three amino acid substitutions, or (xii) the first FR comprises SEQ ID NO: 90 or a variant thereof having one, two, three, four, five or six amino acid substitutions, the second FR comprises SEQ ID NO: 92 or a variant thereof having one, two, three, or four amino acid substitutions, the third FR comprises SEQ ID NO: 94 or a variant thereof having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions, and the fourth FR comprises SEQ ID NO: 96 or a variant thereof having one, two, or three amino acid substitutions. Accordingly, the invention provides in one aspect an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, comprising a first framework region (FR1), a second framework region (FR2), a third framework region (FR3), and a fourth framework region (FR3) wherein, (i) FR1 comprises SEQ ID NO: 2 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 4 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 6 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 8 or a variant thereof having up to three amino acid substitutions; or (ii) FR1 comprises SEQ ID NO: 10 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 12 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 14 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 16 or a variant thereof having up to three amino acid substitutions; or (iii) FR1 comprises SEQ ID NO: 18 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 20 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 22 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 24 or a variant thereof having up to three amino acid substitutions; or (iv) FR1 comprises SEQ ID NO: 26 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 28 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 30 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 32 or a variant thereof having up to three amino acid substitutions; or (v) FR1 comprises SEQ ID NO: 34 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 36 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 38 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 40 or a variant thereof having up to three amino acid substitutions; or (vi) FR1 comprises SEQ ID NO: 42 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 44 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 46 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 48 or a variant thereof having up to three amino acid substitutions; or (vii) FR1 comprises SEQ ID NO: 50 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 52 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 54 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 56 or a variant thereof having up to three amino acid substitutions; or (viii) FR1 comprises SEQ ID NO: 58 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 60 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 62 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 64 or a variant thereof having up to three amino acid substitutions; or (ix) FR1 comprises SEQ ID NO: 66 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 68 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 70 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 72 or a variant thereof having up to three amino acid substitutions; or (x) FR1 comprises SEQ ID NO: 74 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 76 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 78 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 80 or a variant thereof having up to three amino acid substitutions; or (xi) FR1 comprises SEQ ID NO: 82 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 84 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 86 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 88 or a variant thereof having up to three amino acid substitutions; or (xii) FR1 comprises SEQ ID NO: 90 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 92 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 94 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 96 or a variant thereof having up to three amino acid substitutions. As mentioned herein above, a sdAb of the present invention can preferably comprise three CDRs and four FRs. Accordingly, a sdAb preferably comprises a first FR, a first CDR, a second FR, a second CDR, a third FR, a third CDR and a fourth FR. A sdAb of the present invention can consist of a first FR, a first CDR, a second FR, a second CDR, a third FR, a third CDR and a fourth FR. A sdAb of the present invention can comprise any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. A sdAb of the present invention can also consist of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. As described herein above for the individual CDRs and FRs, the sdAb can also comprise amino acid substitutions that essentially do not interfere with its function or structural integrity. A sdAb of the present invention can comprise any number of amino acid substitutions as long as it can still be used according to the invention. Accordingly, the present invention also provides variants of a sdAb of the present invention having 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity when compared to the sdAb. Preferably, the invention provides variants of a sdAb of the invention having more than 90%, such as 91, 92, 93, 94, 95, 96, 97, 98, or 99%, or at least 90%, such as 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, or 90-99%, such as 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity when compared to the sdAb. Accordingly, the present invention provides in another aspect an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the sdAb comprises any one of (i) SEQ ID NO: 1 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 1; or (ii) SEQ ID NO: 9 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 9; or (iii) SEQ ID NO: 17 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 17; or (iv) SEQ ID NO: 25or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 25; or (v) SEQ ID NO: 33 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 33; or (vi) SEQ ID NO: 41 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 41; or (vii) SEQ ID NO: 49 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 49; or (viii) SEQ ID NO: 57 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 57; or (ix) SEQ ID NO: 65 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 65; or (x) SEQ ID NO: 73 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 73; or (xi) SEQ ID NO: 81 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 81; or (xii) SEQ ID NO: 89 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 89. As mentioned herein above, the sdAbs of the invention can embody a specific on-rate constant (kon) and off-rate constant (koff). sdAbs within the ranges defined herein have the advantage that they can associate and dissociate with CRP over time. This means that a continuous and repeated association followed by dissociation with CRP is achieved. This is particularly desired when the sdAbs are used in a measurement over time where the dynamic level of CRP is to be determined. As described herein, determining and monitoring the dynamic level of CRP is particularly advantageous for determining inflammation spikes, such as during the course of a disease or to monitor inflammatory reactions, e.g. to a treatment or drug. Accordingly, it is preferred herein, that the anti-CRP sdAbs of the present invention continuously and reversibly bind CRP. The reversible binding of CRP is particularly desired when the sdAbs are used on a sensor, e.g. biosensor. A sdAb having exceptionally high affinity cannot dissociate from CRP and thus is not feasible in a measurement of dynamic CRP levels over time. The present invention provides anti-CRP sdAbs within konand koffranges allowing continuous and reversible binding of CRP. For example, a sdAb of the invention can bind or associate with an CRP, followed by dissociation from said CRP. After dissociation from the first CRP, the same sdAb can bind a second (other) CRP. After dissociation from the second CRP, the same sdAb can bind a third (other) CRP. Association and dissociation of any further CRP can be repeated as described before. Thus, the sdAbs of the present invention can associate and dissociate a multitude of CRP (reversible binding), enabling measurement of dynamic CRP levels over time (continuous binding). Accordingly, the invention provides in one aspect an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb continuously and reversibly binds CRP. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2, wherein the anti-CRP sdAb continuously and reversibly binds CRP. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 4.60 x 10^6 and an off-rate constant (koff) of about 2.60 x 10^-4 – 2.20 x 10^-1, wherein the anti-CRP sdAb continuously and reversibly binds CRP. The invention also provides an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3, wherein the anti-CRP sdAb continuously and reversibly binds CRP. The invention also provides in one aspect an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb binds a second or further CRP after dissociating from a first CRP. The invention also provides in one aspect an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.80 x 10^5 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 1.30 x 10^-2, wherein the anti-CRP sdAb binds a second or further CRP after dissociating from a first CRP. The invention also provides in one aspect an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 4.60 x 10^6 and an off-rate constant (koff) of about 2.60 x 10^-4 – 2.20 x 10^-1, wherein the anti-CRP sdAb binds a second or further CRP after dissociating from a first CRP. The invention also provides in one aspect an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 4.10 x 10^4 – 3.80 x 10^5 and an off-rate constant (koff) of about 2.00 x 10^-5 – 6.90 x 10^-3, wherein the anti-CRP sdAb binds a second or further CRP after dissociating from a first CRP. As mentioned herein above, the herein provided anti-CRP sdAbs can associate and dissociate with CRP (over time). Accordingly, the present invention provides for anti-CRP sdAbs that are, inter alia, particularly useful in the detection and / or quantification of CRP across a broad range of CRP concentrations. As is further detailed herein below, due to the high (i.e., µM) CRP concentrations in a biological fluid, e.g. human blood even at baseline inflammation (see, for example, Table 1), in the context of the present invention it is particularly advantageous that the herein provided anti-CRP sdAbs, due to their advantageous binding affinities (and konand koffvalues), are able to detect and / or quantify CRP concentrations throughout the entire inflammation range from baseline to severe inflammation (i.e., µM) in a biological fluid, e.g. human blood (see, for example, Table 12 or 13). Accordingly, the present invention provides for an anti-C-reactive protein (CRP) single-domain antibody (sdAb) capable of detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for an anti-C-reactive protein (CRP) single-domain antibody (sdAb) capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3H6 (or variants thereof), capable of detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more , optionally in a human biological fluid. Accordingly, the present invention provides for anti-CRP sdAb SCR-3H6 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3A4 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3A4 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-1A1 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-1A1 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3E5 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3E5 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3B7 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3B7 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3H1 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3H1 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-2D2 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-2D2 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-2B4 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-2B4 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-2D1 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-2D1 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3E4 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3E4 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3G7 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3G7 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. In particular, the present invention provides for anti-CRP sdAb SCR-3A5 (or variants thereof), detecting and / or quantifying CRP concentrations of about 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more, optionally in a human biological fluid. Accordingly, the present invention provides for anti- CRP sdAb SCR-3A5 (or variants thereof), capable of detecting and / or quantifying baseline to severe inflammation, such as baseline inflammation and / or low inflammation and / or moderate inflammation and / or severe inflammation, optionally in a human biological fluid. As is detailed in Table 12 and 13, the herein provided anti-CRP sdAbs can all, inter alia, can detect the entire inflammatory range of CRP and can, accordingly, quantify and / or detect CRP concentrations of, inter alia, 0.01 µM or less to 1 µM or more, such as 0.01 µM or less and / or 0.01 µM to 0.1 µM and / or 0.1 µM to 1 µM and / or 1 µM or more , optionally in a human biological fluid. Accordingly, in the context of the present invention, if any herein provided sdAb detects and / or quantifies moderate inflammation, this means that said antibody detects and / or quantifies baseline inflammation to moderate inflammation (i.e., baseline inflammation, low inflammation, and moderate inflammation). This similarly applies to baseline, low, moderate and severe inflammation. Accordingly, in the context of the present invention, if any herein provided sdAb detects and / or quantifies CRP concentrations of about or more than about 0.1 µM, this means that said antibody detects and / or quantifies CRP concentrations of about 0.01 µM (or less than about 0.01 µM) to about or more than about 0.1 µM. The herein provided anti-CRP sdAbs SCR-3E4, SCR-3G7, SCR-2D1, SCR-1A1, SCR-3B7, SCR-2D2, SCR-3E5, SCR-2B4, SCR-3H1, SCR-3H6, SCR-3A4, SCR-3A5 may in the context of the present invention be defined as detailed herein above or below, by any function characterization detailed in, inter alia, Table 13, and / or by any of the sequences (e.g., CDRs, CDRs and FRs, full length sequences) summarized in Table 14 and provided in the enclosed sequence listing. As is also mentioned herein, such sdAbs (or the respective CDR, FR, or full length sequences) may comprise up to five amino acid substitutions. Accordingly, they may comprise about 1, about 2, about 3, about 4, or about 5 amino acid substitutions. Table 13 – Summary characteristics of exemplary sdAbs provided herein. The column “Covered inflammation range” in the table below indicates the respective inflammation range that a given sdAb can at least partly cover (i.e., any inflammation range that is indicated with “*” in Table 12) or fully cover (i.e., any inflammation range that is indicated with “**” in Table 12). All other columns summarize data also already detailed herein above. * kd too slow to be accurately calculated Antibodies in general can be used to inhibit the biological function of their targets. One advantage of sdAb is that they do not necessarily inhibit the biological function of their targets. In the sense of the present invention, both can be desired, i.e. inhibition of biological function in the sense of a treatment or a non-inhibiting sdAb, in the sense of monitoring CRP levels together with a treatment or independent thereof. Accordingly, the present invention provides sdAbs that do not inhibit the biological function of CRP. In another aspect, the present invention provides sdAbs that do inhibit the biological function of CRP. As used herein “biological function of CRP” relates in general to any effect of CRP, i.e. relates to anything that CRP “does”. This can include any function related to CRP or CRP signalling or the CRP signalling pathway. The biological function of CRP also includes upstream and downstream effects of and on CRP that may be related to CRP or the corresponding inflammation response. Accordingly, the invention provides in one aspect an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb inhibits the biological function of CRP. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb inhibits the biological function of CRP, wherein the biological function of CRP is CRP signalling or the CRP signalling pathway. In another aspect, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb does not inhibit the biological function of CRP. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb does not inhibit the biological function of CRP, wherein the biological function of CRP is CRP signalling or the CRP signalling pathway. As mentioned above, a sdAb of the present invention is particularly useful as a sensor, such as a biosensor. In general, a biosensor is an object used for the detection of a substance. A biosensor can combine a biological component, e.g. sdAb of the invention, with a physiochemical detector. When used in a biosensor, the biological component (sdAb) can associate with CRP, and the physiochemical detector then detects the association / binding. As mentioned above, the sdAb of the invention can continuously and reversibly associate with and dissociate from CRP allowing the physiochemical detector to measure association / dissociation and therefore CRP levels over time. In the sense of the present invention, the physiochemical detector can be an electrochemical detector. In general, the invention is not particularly limited to the use of any physiochemical detector, rather any physiochemical detector that allows a quantitative readout of the association / dissociation of anti-CRP sdAb of the present invention can be used. Exemplary physiochemical detectors that can be used to quantify anti-CRP sdAb association / dissociation with CRP are described herein below. The biosensor of the present invention comprises at least, a sdAb of the present invention, at least one working electrode (also known as the sensing or redox electrode) and a substrate (structural element). Association of CRP with the sdAb induces an electrical signal in the working electrode which allows for a quantitative measurement of CRP association. The electric signal that is generated can be readout by any electrochemical detection techniques commonly used, such as amperometry, chronoamperometry, potentiometry, conductometry, voltammetry, cyclic voltammetry, galvanic cell, impedance spectroscopy, and the like. A working electrode used in the biosensor may comprise any conductive material, such as carbon, metal or alloy, or a metallic compound. An exemplary carbon-based material that can be used in the working electrode is graphite. An exemplary metal or alloy that can be used in the working electrode is platinum, gold or a gold alloy. Exemplary metallic compounds are silicon, ruthenium dioxide or titanium dioxide. In some embodiments, a biosensor electrode can be or comprise a glassy carbon electrode, a carbon nanotube-modified electrode, an indium tin oxide (ITO) electrode, a platinum electrode, a silver electrode, a gold electrode, or a palladium electrode. In some embodiments, a biosensor electrode can be or comprise a gold nanostructured microelectrode or a gold wire electrode. In the sense of the present invention a biosensor electrode can be or comprise a working electrode and / or a counter electrode and / or a reference electrode. In some embodiments a biosensor electrode can be or can comprise a working electrode. In some embodiments a biosensor electrode can be or can comprise a counter electrode. In some embodiments a biosensor electrode can be or can comprise a reference electrode. In a non-limiting example, a biosensor can comprise a working electrode (known as transduction element, where the biochemical reaction happens), a counter electrode (to close the circuit and allow current to flow between working and counter electrode), a substrate (where the electrodes are deposited on) and a reference electrode (e.g. made from Ag / AgCl), kept at a distance from the reaction site to maintain a known and stable potential. The sdAbs of the present invention can be immobilized on the surface of the working electrode directly, e.g. by physisorption, or indirectly, e.g. by a linker. In the sense of the present invention a linker can be any conventional protein-tag, such as a His-tag (linking a sdAb to metal ions immobilized on working electrode), Strep-tag (linking a sdAb to Strep-tactin immobilized on working electrode), SpyTag (linking a sdAb to SpyCatcher immobilized on working electrode) or FLAG-tag (linking a sdAb to anti-FLAG-tag monoclonal antibodies immobilized on working electrode). A linker can also be any conventional protein-tag suitable for chemo-enzymatic conjugation, such as for Sortase-mediated linkage (linking an LPXTG-tagged sdAb to amines / lysines modified working electrode interface), BirA-mediated linkage (introducing biotin on sdAb, which then links to a strepdavidin or avidin modified working electrode interface), Lipoic Acid Ligase (LpIA)-mediated linkage (covalently attaching an azide bearing lipoic acid derivative on sdAb, which can then can be immobilized on sensor through azide- alkyne click chemistry), Tubulin tyrosine ligase (TTL)-mediated linkage (catalyzes the addition of tyrosine derivatives to an engineered Tub-tag, which enables subsequent bioorthogonal reactions with a great variety of probes or effector molecules immobilized on working electrode), or Transglutaminase-mediated linkage (catalyses the formation of stable isopeptide bond between glutamine on c-myc-tag and various primary amine functionalized proteins / substrates). A linker can also be any conventional chemistry techniques including click chemistry and copper-free click chemistry, such as EDC / NHS chemistry (linking primary amines presents on sdAb to a carboxylic acid terminated working electrode), maleimide / cysteine chemistry (linking cysteines presents on sdAb to a maleimide terminated working electrode), or DBCO chemistry (forming covalent triazole linkage to azide modified molecules). A linker can further comprise an amino acid sequence ("peptide tether"), a single- or double-stranded nucleic acid sequence ("ssDNA or dsDNA tether"), Polyethylenglycol (PEG) chains, or combinations thereof, acting as a bridge between the linker on the sdAb to the working electrode. A linker can comprise double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), charged polymers, uncharged polymers, or any combination thereof. A linker can be negatively charged and comprise a DNA / DNA duplex, a peptide nucleic acid (PNA) / DNA duplex, a PNA / PNA duplex where one or both of the PNA are modified with negative charged amino acids, a rigid anionic polyelectrolyte, a rigid negatively charged peptide, or any combination thereof. A linker can also be positively charged and comprise a PNA / PNA duplex with lysines, a rigid cationic polyelectrolyte, a rigid positively charged peptide, or any combination thereof. A linker can have a length ranging from about 5 nm to about 20 nm. In some embodiments, a linker comprises ssDNA having a length ranging from about 10mer to about 100mer. In some embodiments, a linker comprises a dsDNA having a length ranging from about 15mer to about 60mer. In some embodiments a linker is a rigid linker. Alternatively, it may be preferred that a sdAb is directly immobilized (e.g.: via thiol-gold chemistry) on a gold working electrode surface. A DNA tether may also be used to bind the sdAb to the working electrode. In this case sdAbs are coupled to one end of a DNA tether via maleimide-cysteine chemistry. While the other end of the DNA strand is attached to the gold working electrode via thiol-gold chemistry. The linker can further comprise a detection label or a tag as defined herein, e.g. a redox reporter or an enzyme. A redox reporter can be bound to the linker. A linker can have a first end and a second end, the first end of the linker can be bound to a surface of a biosensor electrode, e.g. working electrode, the second end can be bound to an anti- CRP sdAb of the present invention. The sequence of the sdAb of the present invention, i.e. SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 may be modified to include a linker sequence. The sdAb and working electrode may be attached to a substrate as a structural element. Exemplary substrates that can be used in the biosensor are glass, or ceramic or plastic (e.g.: flexible / semirigid polyimide). The biosensor of the present invention can further comprise a counter electrode and / or a reference electrode. The reference electrode, e.g. made from Ag / AgCl, is kept at a distance from the reaction site in order to maintain a known and stable potential. The working electrode serves as the transduction element in the biochemical reaction, while the counter electrode establishes a connection to the electrolytic solution so that a current can be applied to the working electrode. These electrodes preferably are conductive and chemically stable (see e.g. Grieshaber, Dorothee, et al. "Electrochemical biosensors-sensor principles and architectures." Sensors 8.3 (2008): 1400-1458.). The biosensor of the present invention can further comprise a detection label or a tag, e.g. a redox reporter or an enzyme. Exemplary redox reporters / indicators are ferrocene, [Co(GA)2(phen)] (GA=glycolic acid, phen=1,10-phenathroline), methylene blue, metal nanoparticles (e.g., Au, Pt, Pd, Ag, Cu), pyrroloquinoline quinone (PQQ), benzoquine, Osmium(III) complexes such as Os(bpy)Cl23+, diphenylamine, or any combination thereof. These can e.g. be incorporated into a DNA linker and can be oxidized at an electrode potential, generating a measurable faraday current (see e.g. Das, Jagotamoy, et al. "Reagentless biomolecular analysis using a molecular pendulum." Nature chemistry 13.5 (2021): 428-434.) Such a tag can be comprised in or fused e.g. to the sdAb of the present invention. A tag can be fused for example to the C-terminus or the N-terminus of a sdAb of the invention. A tag can also be comprised in a linker as disclosed herein. A sdAb of the invention can for example comprise a Cysteine-tag, a fluorescence tag, a metal tag or a poly-histidine tag (His-tag). Use of such a tag is optional for the biosensor as described herein. As used herein “conjugated” preferably means that a sdAb of the present invention is linked to / bound to / layered on to / attached to a surface of a biosensor electrode, such as a working electrode. In the sense of the present invention, an anti-CRP sdAb can be comprised in a biosensor or can be part of a biosensor. A sdAb of the present invention may be attached to a surface of a biosensor electrode via a linker as disclosed herein or can physically be deposited (e.g. primarily by van der Waals forces) onto the surface of a biosensor electrode via adsorption physiosorption. Accordingly, “conjugated” as used herein can also mean physical deposition onto the surface of a biosensor electrode via adsorption physiosorption. As used herein “conjugated to a working electrode” can also be “conjugated to a biosensor electrode”. Accordingly, the invention provides in one aspect a biosensor comprising a sdAb of the present invention and a working electrode. The invention also provides a biosensor comprising a sdAb of the present invention and a working electrode, wherein the sdAb is conjugated to the working electrode. The invention also provides a biosensor comprising a sdAb of the present invention and a working electrode, wherein the sdAb is conjugated to the working electrode via a linker. The invention also provides a biosensor comprising a sdAb of the present invention and a working electrode, wherein the sdAb is conjugated to the working electrode via a linker, wherein the linker is selected from the group of: (i) protein-tag, such as His-tag, Strep-tag, SpyTag, or FLAG-tag, (ii) protein-tag suitable for chemo-enzymatic conjugation, such as for Sortase-mediated linkage, BirA-mediated linkage, Lipoic Acid Ligase (LpIA)-mediated linkage, Tubulin tyrosine ligase (TTL)-mediated linkage, Transglutaminase-mediated linkage, (iii) conventional chemistry techniques, such as click chemistry, copper-free click chemistry, EDC / NHS chemistry, maleimide / cysteine chemistry, or DBCO chemistry, (iv) amino acid sequence, such as a peptide tether, (v) nucleic acid sequence, such as a single stranded DNA or a double stranded DNA, (vi) Polyethylenglycol (PEG). The invention also provides a biosensor comprising a sdAb of the present invention and a working electrode, wherein the sdAb is conjugated to the working electrode, and a counter electrode and / or a reference electrode, and a substrate. The invention also provides a biosensor comprising at least a sdAb of the present invention and a working electrode, and a substrate. The invention also provides a biosensor comprising a sdAb of the present invention and a working electrode, wherein the working electrode comprises a conductive material, such as carbon, metal or metallic compound. The invention also provides a biosensor comprising a sdAb of the present invention and a working electrode, wherein the sdAb comprises a detection label or tag. In another aspect, the invention provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb is conjugated a working electrode. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb is conjugated to a working electrode via a nucleic acid (linker). The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb is conjugated to a working electrode, further comprising a counter electrode and / or a reference electrode, and a substrate. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1 in a biosensor, comprising at least an anti-CRP sdAb of the present invention, a working electrode, and a substrate. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb is conjugated a working electrode, wherein the working electrode comprises a conductive material, such as carbon, metal or metallic compound. The invention also provides an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1, wherein the anti-CRP sdAb is conjugated a working electrode, wherein the sdAb comprises a detection label or tag. It is envisioned herein that a sdAb of the invention can be combined with other antibodies e.g. other antibodies / sdAbs binding CRP or other antibodies / sdAbs binding any other / further targets. It is also envisioned herein, that one or more anti-CRP sdAb of the invention can be combined in the products, methods, uses and purpose limited products provided herein. Accordingly, one or more sdAbs of the present invention can be any one of the sdAbs defined in SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. Similarly, two or more sdAbs of the present invention can be any one of the sdAbs defined in SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. In the sense of the present invention “one or more sdAb of the present invention” preferably means one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAbs selected from the group of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. In the sense of the present invention “two or more sdAb of the present invention” preferably means two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAbs selected from the group of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. The present invention also provides a nucleic acid encoding an anti-CRP sdAb of the invention. A “nucleic acid” in the sense of the present invention is a polymer of nucleotides, such as a polynucleotide. A nucleic acid can be any nucleic acid, preferably a deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA). A nucleic acid encoding an anti-CRP sdAb of the invention is particularly useful for producing the sdAb of the invention. For example, a nucleic acid can comprise a DNA plasmid or DNA vector encoding an anti-CRP sdAb of the invention. A DNA plasmid or DNA vector can comprise additional elements that aid the transcription and translation of the sdAb in a host cell, such as artificial or viral promoters. For example, a DNA plasmid or DNA vector can further comprise a strong viral promoter, such as the simian vacuolating virus 40 (SV40) promoter, the Rous Sarcoma Virus (RSV) promoter, the cytomegalovirus (CMV) immediate early promoter or a retroviral cis-acting transcriptional element. A DNA plasmid or DNA vector can further comprise strong polyadenylation / transcriptional termination signals, such as bovine growth hormone or rabbit beta-globulin polyadenylation sequences. A DNA plasmid or DNA vector can further comprise modifications, such as insertion of enhancer sequences, synthetic introns, adenovirus tripartite leader (TPL) sequences and modifications to the polyadenylation and transcriptional termination sequences. The DNA plasmid or DNA vector of the present invention can be codon optimized for expression in a host, host cell or organism. Useful hosts, host cells or organisms for sdAb production are for example viruses or bacteria, such as bacteriophages, Escherichia coli, E. coli strain BL21, E. coli strain TG1, yeast, insect cells, or mammalian cells. For example the E. coli strain BL21 or E. coli strain TG1 can be used to produce sdAbs of the present invention. The DNA of the present invention can be single-stranded DNA or double-stranded DNA. The DNA of the present invention is preferably double stranded. The nucleic acid, such as a DNA, of the present invention can be present in a host cell, e.g. for the purpose of expressing or producing a sdAb of the invention. Accordingly, the invention provides a host cell comprising a nucleic acid encoding an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. The invention also provides a nucleic acid encoding an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. In another aspect, the invention provides a DNA encoding an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. In another aspect, the invention provides a DNA vector encoding an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. In another aspect, the invention provides a DNA expression vector encoding an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. In another aspect the invention provides a RNA encoding an anti-CRP sdAb of the invention. A sdAb of the present invention can be encoded by e.g. a messenger ribonucleic acid (mRNA) which is typically a single-stranded molecule of RNA that can be used by a ribosome for peptide synthesis. In the sense of the present invention a RNA encoding an anti-CRP sdAb of the invention is preferably a mRNA. The mRNA encoding an anti-CRP sdAb of the invention is delivered to a host cell where it is translated into an anti-CRP sdAb or can be used in in vitro transcription. In general, any mRNA construct encoding an anti-CRP sdAb that is capable of expressing an anti-CRP sdAb can be used in the sense of the present invention. Accordingly, the invention provides a RNA encoding an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. In another aspect, the invention provides a mRNA encoding an anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. The skilled person is aware that, except where otherwise noted, polynucleotide sequences set forth in the present application will recite “T”s in a representative DNA sequence but where the sequence represents RNA (e.g., mRNA), the “T”s would be substituted for “U”s. Thus, any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each “T” of the DNA sequence is substituted with “U”. A mRNA can comprise at least an open reading frame encoding an anti-CRP sdAb of the present invention. The basic components of an mRNA molecule typically include at least one coding regions, a 5’ untranslated region (UTR), a 3’ UTR, a 5’ cap and a poly-A tail. Polynucleotides of the present invention may function as mRNA but can be distinguished from wild-type mRNA in their functional and / or structural design features which serve to overcome existing problems of effective polypeptide expression e.g. when using nucleic-acid based therapeutics or when used for optimized expression / production of sdAbs. The mRNAs of the present invention may be codon optimized for expression in a host, host cell or organism. The nucleic acid, such as a RNA, of the present invention can be present in a host cell, e.g. for the purpose of expressing or producing a sdAb of the invention. Accordingly, the invention provides a host cell comprising a RNA encoding an anti-C-reactive protein (CRP) single- domain antibody (sdAb) comprising an on-rate constant (kon) of about 3.30 x 10^4 – 1.70 x 10^7 and an off-rate constant (koff) of about 3.20 x 10^-9 – 2.20 x 10^-1. The sample and / or biological fluid to be used and / or analyzed herein preferably have a physiological pH, e.g. about 7.0 to about 7.5, preferably about 7.2 to 7.4. For example, the pH of (arterial) blood normally is within a range of about 7.35-7.45. Intracellular pH (e.g. pH of interstitial fluid) can range between about 7.03 to 7.46. It is preferred herein that he sample and / or biological fluid is blood or interstitial fluid. The invention also provides a method for detecting and / or quantifying CRP, e.g. in a sample. Such a method makes use of the sdAbs provided herein which specifically bind CRP within the entire dynamic range of the CRP level. As described herein above, it is especially useful to detect and / or quantify CRP levels in a sample to evaluate the inflammation status of a subject or monitor efficacy and tolerability of a treatment. Such a method can comprise contacting a sample with an anti-CRP sdAb of the invention and detecting and / or quantifying binding of the anti-CRP sdAb. A sample used in the sense of the present invention can be any sample that allows for detection and / or quantification of CRP levels. A sample can be for example wherein a biological fluid, such as a bodily fluid. Exemplary samples are interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like. Accordingly, the invention provides in one aspect a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the sample comprises interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva. Similarly, the invention is not limited to means of contacting a sample, any means that are feasible for contacting an CRP with an anti-CRP sdAb of the invention can be used. Exemplary means of contacting a sample with an anti-CRP sdAb of the invention are collection through a finger stick / prick or syringe and deposition on the anti-CRP sdAb and / or biosensor, collection through microfluidic or capillary-based system to the anti-CRP sdAb and / or biosensor surface, collection through needle or microneedle-based system, direct implantation of the biosensor comprising the anti-CRP sdAb in contact with the bodily fluid of interest. Other means of contacting a sample with an anti-CRP sdAb and / or biosensor of the invention comprise determining a body site where to collect a sample (e.g. bodily fluid) from (ex vivo) and / or contacting a sample (e.g. body fluid) with the anti-CRP sdAb and / or the biosensor (in vivo). In the sense of the present invention, a sample may be contacted with an anti-CRP sdAb conjugated to a working electrode in a biosensor. Similarly, a sdAb conjugated to a working electrode in a biosensor may be contacted with an CRP or a sample comprising CRP. Accordingly, the invention provides in one aspect a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the contacting step comprises contacting a sample via a syringe, a needle, a microfluidic or capillary-based system with the anti-CRP sdAb of the invention. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the contacting step comprises contacting the sample with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In general, the invention is not limited to any means of detecting a sdAb, an CRP and / or an CRP bound by a sdAb of the present invention. Any means allowing for detection / quantification can be used in the sense of the invention. Exemplary antibody-based detection methods are well known in the art, and include, for example, ELISA, electrochemical ELISA, immunoblots, radioimmunoassays, immunofluorescence, immunoprecipitation, and other related techniques. Association of a sdAb of the invention and CRP can also be physiochemically such as electrochemically detected / quantified using physiochemical or electrochemical techniques as described herein. The electric signal that is generated can be readout by any electrochemical techniques commonly used, such as amperometry, chronoamperometry, potentiometry, conductometry, voltammetry, cyclic voltammetry, galvanic cell, impedance spectroscopy, and the like resulting in detection / quantification of sdAb and CRP association. It is preferred herein, that CRP levels are detected / quantified making use of the biosensor as described herein above. Accordingly, the method for detecting and / or quantifying CRP in a sample can be performed using a biosensor as described herein, such as a biosensor comprising a sdAb of the invention conjugated to a working electrode. Accordingly, the invention provides in one aspect a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the detection step comprises physiochemical or electrochemical detection of the binding of the anti-CRP sdAb and CRP. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the detection step comprises detection of the binding of the anti-CRP sdAb and CRP via an electrical signal produced by the binding. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the detection step comprises detection of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In a preferred aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the contacting step comprises contacting the sample with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode and, wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. Electrochemical ELISA can be used as an exemplary means for detecting and / or quantifying CRP or in a detecting unit for detecting and / or quantifying CRP. In brief, the anti-CRP sdAb can be directly or indirectly immobilized / conjugated to a working electrode. The working electrode can be incubated with samples (e.g. interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva) to be tested for CRP levels. During incubation, CRP can bind to the anti-CRP sdAb. After incubation, the working electrode can be washed, e.g. with phosphate buffered saline (PBS). A solution with a secondary antibody (i.e. antibody binding the anti- CRP sdAb) modified with biotin can be added and incubated, followed by another washing step of the working electrode. A solution containing streptavidin modified enzyme, such as alkaline phosphatase (ALP), polymeric alkaline phosphatease (PALP), or Horseradish Peroxidase (HRP), can be added to the working electrode, followed by another washing step of the working electrode. A solution containing enzyme substrate such as 4-APP, ABTS, AEC, DAB, ECL, TMB, Amplex Red, BCIP / NBT (5-Bromo-4-chloro-3-indolyl phosphate along with nitro blue tetrazolium), pNPP (para-Nitrophenylphosphate), or Fast Red, can then be added, and the electrochemical oxidation signal can be recorded, e.g. by using differential pulse voltammetry. An alternative approach of applying electrochemical ELISA is to directly or indirectly immobilize / conjugate the anti-CRP sdAb to a working electrode. The working electrode can be incubated with samples (e.g. interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva) to be tested for CRP levels. During incubation, CRP can bind to the anti-CRP sdAb. After incubation, the working electrode can be washed, e.g. with phosphate buffered saline (PBS). A solution with a secondary antibody (i.e. antibody binding the anti-CRP sdAb) modified with an enzyme, such as alkaline phosphatase (ALP), polymeric alkaline phosphatease (PALP), or Horseradish Peroxidase (HRP), can be added and incubated, followed by another washing step of the working electrode. A solution containing enzyme substrate such as 4-APP, ABTS, AEC, DAB, ECL, TMB, Amplex Red, BCIP / NBT (5-Bromo-4-chloro-3- indolyl phosphate along with nitro blue tetrazolium), pNPP (para-Nitrophenylphosphate), or Fast Red, can then be added, and the electrochemical oxidation signal can be recorded, e.g. by using differential pulse voltammetry. Biosensing via electrochemical ELISA is for example disclosed in Arya, Sunil K., and Pedro Estrela. "Electrochemical ELISA protein biosensing in undiluted serum using a polypyrrole- based platform." Sensors 20.10 (2020): 2857. Accordingly, the invention provides in one aspect, a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the detection step comprises detection of the binding of the anti-CRP sdAb and CRP via electrochemical ELISA. The method for detecting and / or quantifying CRP in a sample as described above can be ex vivo or in vitro. Accordingly, the invention provides in one aspect an ex vivo or in vitro method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with an anti-CRP sdAb of the present invention, and (ii) detecting binding of the anti-CRP sdAb. In some aspects of the invention, the methods described herein can further comprise quantifying the CRP level in a sample or a subject and comparing the CRP level with a reference sample or value. A reference sample may be a sample comprising an CRP level corresponding to any specific inflammation conditions, such as inactive and active IBD, COVID, cancer, sepsis, and septic shock. A reference sample may be a standardized sample, i.e. a sample comprising CRP levels that have been standardized to certain CRP levels. Such CRP levels may correspond to values or ranges of CRP levels indicating e.g. baseline inflammation, low inflammation, moderate inflammation, high inflammation or severe inflammation in a sample or subject. Accordingly, the CRP level in a sample or a subject may also be compared to a CRP level value. An CRP level value can be obtained from a reference sample as described herein or e.g. from the literature. CRP level reference sample or values and thereby the inflammation status they indicate may vary dependent on the subject, the disease a subject may be suffering from and / or the treatment a subject is receiving. The skilled practitioner is aware and knows what reference samples or values can be used to properly assess a subject’s inflammation status. Exemplary reference values may be obtained from Devran et al., 2012, Dinh et al., 2019, Hart et al., 2020, Herieka & Erridge, 2014, Keegan et al., 2020, Landry et al., 2017, Mavropoulou et al., 2020, Póvoa et al., 1998, Ridker et al., 2003, Ruiz-González et al., 2016, Sproston & Ashworth, 2018.. For example, the following reference values may be used: Table 1: CRP concentrations in humans during homeostasis and disease. Detection and / or quantification of CRP in a sample as described herein above can for example be realized by a spot measurement of the CRP levels making use of the sdAb of the present invention. For example, the method for detecting and / or quantifying CRP can comprise obtaining a sample from a subject, contacting the sample with an anti-CRP sdAb of the invention, and detecting binding of the anti-CRP sdAb. The method can further comprise quantifying the CRP level in the sample, which correlates with the binding kinetics between sdAb and CRP. In an exemplary embodiment, a spot measurement can be realized in the method for detecting and / or quantifying CRP comprising obtaining a sample from a subject e.g. obtaining a drop of blood by fingerpick, contacting the sample with an anti-CRP sdAb of the invention e.g. collecting the sample through capillary mechanisms or deposition onto an anti- CRP sdAb or a biosensor comprising the same as disclosed herein, detecting binding of the anti-CRP sdAb, thereby quantifying the CRP level in the sample and the subject. In some embodiments of the method, the anti-CRP sdAb may be conjugated to a working electrode in a biosensor as described herein. Accordingly, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. The method can be repeated for samples from individual subjects. This is particularly desired when the development or dynamics of the CRP levels in a subject are relevant for a therapy of the subject. Rising levels of CRP over time correlate with increased inflammation, while declining levels of CRP over time correlate with reduced inflammation. For example, a rising level of CRP can indicate an infectious disease. Particularly, the CRP levels can be useful to indicate whether a subject suffers from a bacterial or viral infection. CRP levels are elevated in subjects suffering from infection, when treated with antibiotics, CRP levels will decline if the subject suffers from a bacterial infection. In contrast, when treated with antibiotics, CRP levels will not decline if the subject suffers from viral infection. Accordingly, it is especially useful to monitor the CRP levels in a subject over time, e.g. to arrive at a clinical conclusion of the best treatment of a subject. By repeating the spot measurement as described above, the dynamic CRP level in a subject can be detected over time allowing the skilled practitioner to make reasoned treatment decisions, e.g. in case of bacterial vs. viral infection. In addition, CRP levels can correlate with inflammation spikes in inflammatory diseases and / or autoimmune diseases. Exemplary inflammatory and / or autoimmune diseases in the sense of the invention are rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, tumour and the like. Inflammatory and / or autoimmune diseases may require close medical attention and medication. During the course of an inflammatory and / or autoimmune disease it is especially useful to monitor the CRP levels in a subject. By doing so, inflammation spikes can be detected enabling targeted therapy and medication which reduces the total amount of administered medication needed and thereby potential side effects compared to a continuous treatment. Accordingly, the detection and / or quantification of the CRP levels in a subject enables the skilled practitioner to modulate and personalize the treatment of a subject while reducing the total amount of drugs administered, particularly, if the CRP levels are detected / quantified over time. Thus, the detection and / or quantification of CRP levels over time is desired for improved disease management. In some embodiments, the method for detecting and / or quantifying CRP in a sample does not comprise a step of obtaining a sample from a subject. Accordingly, in one aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising detecting the binding of the anti-CRP sdAb over time. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are performed on a further sample, optionally wherein the sample is from the same subject. In yet another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising contacting and / or detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are performed on a further sample, optionally wherein the sample is from the same subject, and wherein the contacting step comprises contacting the sample with a contacting a sample with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode, and wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In another preferred aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising contacting and / or detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are performed on a further sample, optionally wherein the sample is from the same subject, and wherein the contacting step comprises contacting the sample with a contacting a sample with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode, and wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In another preferred aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising contacting and / or detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are performed on a further sample, optionally wherein the sample is from the same subject, and wherein the contacting step comprises contacting the sample with a contacting a sample with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode, and wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In another preferred aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the detection step comprises detection of the binding of the anti-CRP sdAb and CRP via electrochemical ELISA. It is also envisioned herein to use more than one sdAb of the invention in a method for detecting and / or quantifying CRP in a sample. Two or more anti-CRP sdAb can be used to combine specific desired ranges of on-rate constant (kon) and off-rate constant (koff) to arrive at the desired association and dissociation dynamics. Accordingly, the method for detecting and / or quantifying CRP in a sample of the present invention can comprise contacting a sample with one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the present invention. In some embodiments, the method for detecting and / or quantifying CRP in a sample of the present invention can comprise contacting a sample with two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti- CRP sdAb of the present invention. Accordingly, the invention provides in one aspect a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with one or more anti-CRP sdAb of the invention, and (ii) detecting binding of the one or more anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAbs of the invention, and (ii) detecting binding of the one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAbs. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with two or more anti-CRP sdAb of the invention, and (ii) detecting binding of the two or more anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a sample, the method comprising: (i) contacting a sample with two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the invention, and (ii) detecting binding of the two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb. As described herein, a particular advantage of the sdAb of the invention is the reversible and continuous binding of CRP. Spot measurements as described herein are particularly useful to determine levels of CRP. In another aspect, it is also desired to continuously monitor the levels of CRP in a subject, e.g. avoiding obtaining samples from a subject at multiple time points. Reducing the sample collection steps, e.g. blood draws on a subject, is especially advantageous, since it reduces treatment burden on the subject. For this, the measurement of CRP levels can be in or on a subject, i.e. in vivo. Accordingly, in one aspect the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. In general, the features provided for the method for detecting and / or quantifying CRP in a sample herein above can be applied to the method for detecting and / or quantifying CRP in a subject. In some aspects, it is not necessary to obtain a sample from a subject when a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like is contacted with an anti-CRP sdAb of the invention. When the CRP level is detected on or in the subject, a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like may be contacted directly with an anti-CRP sdAb of the invention, or e.g. a biosensor comprising a sdAb of the invention conjugated to a working electrode. The invention is not particularly limited to any means of contacting, rather any means of contacting that allow a sdAb of the invention to come in close proximity with a CRP of the subject (i.e. that binding / association of an anti-CRP sdAb of the invention and an CRP of the subject is realized) can be used. Exemplary forms of contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like can be via a syringe, a needle, a microfluidic or capillary-based system or the like. In one aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with an anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject’s interstitial fluid (ISF) with an anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. In the sense of the present invention, a subject may be contacted with an anti-CRP sdAb conjugated to a working electrode in a biosensor. Similarly, a sdAb conjugated to a working electrode in a biosensor may be contacted with a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like comprising CRP. Accordingly, the invention provides in one aspect a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the contacting step comprises contacting the subject with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. As described herein above, the method for detecting and / or quantifying CRP can be performed using a biosensor as described herein, e.g. a biosensor comprising a sdAb of the invention conjugated to a working electrode. This can also be applied to the method for detecting and / or quantifying CRP in a subject of the invention. Accordingly, in another aspect the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the contacting step comprises contacting the subject with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode, and wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In another aspect the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, wherein the detection step comprises detection of the binding of the anti-CRP sdAb and CRP via electrochemical ELISA. The method of the invention for detecting and / or quantifying CRP in a subject, can further comprise quantifying the CRP level in a subject and comparing the CRP level with a reference sample or value. Thus, the statements described herein above regarding further comprising quantifying the CRP level and comparing the CRP level with a reference sample or value also apply to the method of the invention for detecting and / or quantifying CRP in a subject. Similarly, to the spot type measurements in a sample as described above, the invention also provides a means to measure the CRP levels in or on a subject over time, i.e. a method for detecting and / or quantifying CRP in a subject over time. Measuring CRP levels over time is especially advantageous when done in or on a subject since no additional samples have to be obtained from the subject reducing the burden on the subject. This allows to reduce the time steps in which the CRP levels are measured in the subject resulting in a superior resolution of the dynamic CRP level in the subject over time. The thereby increased resolution of the dynamic CRP levels in the subject allow the skilled practitioner to precisely modulate and personalize the treatment of a subject while reducing the total amount of drugs administered, particularly. Thus, the detection and / or quantification of CRP levels over time in a subject result in improved disease management. The method for detecting and / or quantifying CRP in or on a subject as described herein can be realizes within a device or apparatus in form of an applicator like appliance, such as a handheld or stationary device comprising the biosensor of the present invention, or in form of a permanently or reversibly implanted or attached (to the subject’s body) like appliance, such as an implanted, wearable device comprising the biosensor of the present invention. As used herein “detecting binding of the anti-CRP sdAb to CRP” in the context of a sdAb comprised in a biosensor or apparatus of the present invention can include or be “detecting an electrochemical signal (optionally where detection of said signal indicates the presence of CRP and / or wherein the signal strength indicates the amount of CRP)”. Devices and apparatuses useful for performing the methods provided herein are described below in more detail. Accordingly, in one aspect the invention provides a method for detecting and / or quantifying CRP in a subject over time, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising contacting and / or detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are repeatedly performed in or on the subject. In a preferred aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising contacting and / or detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are repeatedly performed in or on the subject, and wherein the contacting step comprises contacting the subject with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode, and wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. In another preferred aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb, further comprising contacting and / or detecting the binding of the anti-CRP sdAb over time, wherein steps (i) and (ii) are repeatedly performed in or on the subject, and wherein the contacting step comprises contacting the subject with a biosensor of the invention, optionally wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode, and wherein the detection step comprises detecting the binding of the binding of the anti-CRP sdAb and CRP with a biosensor of the invention, optionally, wherein the biosensor comprises a sdAb of the invention conjugated to a working electrode. It is also envisioned herein to use more than one sdAb of the invention in a method for detecting and / or quantifying CRP in a subject. Two or more anti-CRP sdAb can be used to combine specific desired ranges of on-rate constant (kon) and off-rate constant (koff) to arrive at the desired association and dissociation dynamics. Accordingly, the method for detecting and / or quantifying CRP in a subject of the present invention can comprise contacting a subject with one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the present invention. In some embodiments, the method for detecting and / or quantifying CRP in a subject of the present invention can comprise contacting a subject with two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti- CRP sdAb of the present invention. Accordingly, the invention provides in one aspect a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with one or more anti-CRP sdAb of the invention, and (ii) detecting binding of one or more anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the invention, and (ii) detecting binding of one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with two or more anti-CRP sdAb of the invention, and (ii) detecting binding of two or more anti-CRP sdAb. In another aspect, the invention provides a method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject with two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the invention, and (ii) detecting binding of two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb. It is also encompassed herein that a level of CRP can be detected and / or quantified in sample from a subject or in a subject in its original place, i.e. at the original location of the sample or at the location in a subject (in situ). Thus, the anti-CRP sdAb, the biosensor comprising the same and the apparatuses comprising the same of the present invention are particularly useful for in situ detection and / or quantification of CRP. An in situ method as disclosed herein can comprise or be an in vivo method. Accordingly, the invention provides in one aspect an in situ method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject’s biological fluid or sample e.g. a bodily fluid with an anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. In another aspect, the invention provides an in situ method for detecting and / or quantifying CRP in a subject, the method comprising: (i) contacting a subject’s bodily fluid e.g. interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva with an anti-CRP sdAb of the invention, and (ii) detecting binding of the anti-CRP sdAb. In general, the features provided for the method for detecting and / or quantifying CRP in a subject herein above can also be applied mutatis mutandis to the in situ method for detecting and / or quantifying CRP in a subject. The features described herein in context of the method for detecting and / or quantifying CRP in a sample apply mutatis mutandis to the method for detecting and / or quantifying CRP in a subject. In some aspect, the method for detecting and / or quantifying CRP in a subject may not comprise a step of obtaining a sample from the subject. The methods for detecting and / or quantifying CRP in a sample or in / on a subject can be performed for example in an apparatus or performed by an apparatus. An apparatus comprising components for performing the methods described herein is especially useful for efficient and quick measurement of CRP levels in a sample or in / on a subject. Thus, an apparatus according to the present invention can be used in any spot measurement or any continuous measurement of CRP as described herein. An apparatus of the present invention is not particularly limited, in general, an apparatus comprising an anti-CRP sdAb of the invention and any means of measuring / detecting / quantifying association / binding of the anti-CRP sdAb of the invention to CRP can be used. The apparatus of the present invention can comprise one or more anti-CRP sdAb of the present invention. Using more than one sdAb can be preferred herein to take advantage of the individual properties of anti-CRP sdAb provided herein. For example, a biosensor or apparatus provided herein comprising two or more anti-CRP sdAb can be used to combine specific desired ranges of on-rate constant (kon) and off-rate constant (koff) to arrive at the desired association and dissociation dynamics. In some embodiments, the apparatus of the present invention comprises one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the present invention. In some embodiments, the biosensor of the present invention comprises one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the present invention. In some embodiments, one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the present invention can be used in any of the products, methods or uses of the present invention. Accordingly, the invention provides in one aspect an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the invention, and (ii) a contacting unit for contacting a sample with the one or more anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the one or more anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb of the invention, and (ii) a contacting unit for contacting a subject with the one or more anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the one or more anti-CRP sdAb. The detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb can comprise for example a contacting unit for contacting a sample or a subject with the anti-CRP sdAb of the invention. Such means can be comprised in a first unit which allows a sample or a subject to be contacted. As described above, exemplary forms of contacting a sample or a subject can be via a syringe, a needle, a microfluidic or capillary-based system or the like. A sample to be contacted with the first unit can comprise interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like. The contacting step is in a subject, a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, saliva and the like can be contacted by the first unit. In some embodiments it is preferred that a sample comprises interstitial fluid or blood. In some embodiments it is preferred that a subject’s interstitial fluid or blood is contacted. The detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb can comprise any means that allow a quantitative readout of the association of anti-CRP sdAb and CRP in the sample or subject. The detecting unit for detecting and / or quantifying binding of the anti- CRP sdAb can be comprised in a second unit which allows to detect and / or quantify binding of the anti-CRP sdAb. Accordingly, the detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb of the present invention described in the context of the methods herein also apply to the detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb in the apparatus. For example, an anti-CRP sdAb conjugated to a working electrode, as described herein, can be used as a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb in the apparatus. Similarly, a biosensor as described herein can be used as a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb in the apparatus. Other exemplary detecting units for detecting and / or quantifying binding of the anti-CRP sdAb in the apparatus can include electrochemical, optical, thermal, electronic, gravimetric, or acoustic means of detection. For example, a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb to CRP in the apparatus can comprise electrochemical ELISA. In some embodiments, the first and the second units can be combined in a single unit. In this case, the single unit may be the first unit. Accordingly, the invention provides in one aspect an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample with the anti-CRP sdAb and comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject with the anti-CRP sdAb and comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises the anti-CRP sdAb conjugated to a working electrode. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises the anti-CRP sdAb conjugated to a working electrode. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor of the present invention. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor of the present invention. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor of the present invention. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor of the present invention. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode, wherein the anti-CRP sdAb is conjugated to the working electrode, optionally via a nucleic acid (linker). In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode, wherein the anti-CRP sdAb is conjugated to the working electrode, optionally via a nucleic acid (linker). In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode, a counter electrode and / or a reference electrode, and a substrate, wherein the anti-CRP sdAb is conjugated to the working electrode, optionally via a nucleic acid (linker). In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode, a counter electrode and / or a reference electrode, and a substrate, wherein the anti-CRP sdAb is conjugated to the working electrode, optionally via a nucleic acid (linker). In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample comprising interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode, a counter electrode and / or a reference electrode, and a substrate, wherein the anti-CRP sdAb is conjugated to the working electrode, optionally via a nucleic acid (linker), and wherein the anti-CRP sdAb comprises a detection label or tag. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject’s interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat, or saliva with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, wherein the second unit comprises a biosensor comprising the anti-CRP sdAb and a working electrode, a counter electrode and / or a reference electrode, and a substrate, wherein the anti-CRP sdAb is conjugated to the working electrode, optionally via a nucleic acid (linker), and wherein the anti-CRP sdAb comprises a detection label or tag. It is also envisioned herein that the apparatus of the present invention can comprise additional components, such as means for dispensing a drug, e.g. a dispensing unit for dispensing a drug. The means for dispensing a drug / dispensing unit for dispensing a drug can be comprised in a third unit which is further comprised the apparatus of the invention. For example, the apparatus as described herein can comprise a third unit comprising means for dispensing a drug / a dispensing unit for dispensing a drug. This is advantageous when it is desired to combine the measurement of CRP levels in a subject with a therapy. For example, the measured level of CRP in a subject can be compared with a reference value as described herein above. Depending on the difference of the CRP level in the subject and the reference value, the third unit can dispense a drug, e.g. to counter inflammation or to decrease or increase levels of CRP. In the sense of the present invention, a drug can be any drug used in the treatment of an CRP related disease, such as an inflammatory disease and / or autoimmune disease. Exemplary inflammatory diseases and / or autoimmune diseases are rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, tumour and the like. In general, the invention is not limited to a third unit dispensing a specific drug, the skilled practitioner is aware that any drug suitable for the means of dispensing the drug and for the therapy of the disease to be treated in the subject can be used. Exemplary drugs that can be used in the sense of the invention are remdevisir, nirmatrelvir, molnupiravir, baricitinib, bebtelovimab, etesevimab, casirivimab, imdevimab, aspirin, celecoxib, prednisone, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine, abatacept, adalimumab, certolizumab, etanecept, golimumab, infliximab, rituximab, sarilumab, tocilizumab, baricitinib, tofacitinib, upadacitinib, anakinra, minocycline, azathioprine, cyclosporine, penicillamine, Statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dapagliflozin, ibuprofen, naproxen, voclosporin, anifrolumab, mycophenolate, belimumab, glatiramer acetate, ocrelizumab, fingolimod, dimethyl fumarate, teriflunomide, methylprednisone, natalizumab, alemtuzumab, diroximel fumarate, siponimod, cladribine, Broad-spectrum antibiotics, amlodipine, diltiazem, Metformin, Insulin, SGLT2 inhibitors, leuprolide, anastrozole, letrozole, tamoxifen, fulvestrant, bevacizumab, alectinib, ibrutinib, imatinib, palbociclib, fluoxymesterone, methyltestosterone, tamoxifen citrate, estramustine, interferon alfa-2b recombinant, goserelin, flutamide, aldesleukin, bicalutamide, porfimer, nilutamide, imiquimod, toremifene, thalidomide, trastuzumab, alitretinoin, bexarotene, denileukin dfititox, exemestane, gemtuzumab, triptorelin, imatinib mesylate, peginterferon alfa-2b, ibritumomab tiuxetan, leuprolide acteate, abarelix, bortezomib, gefitinib, tositumomab, cetuximab, erlotinib hydrochloride, azacitidine, lenalidomide, sorafenib tosylate, dastinib, decitabine, panitumumab, sunitinib malate, vorinostat, lapatinib ditosylate, nilotinib, temsirolimus, degarelix, everolimus, ofatumumab, pazopanib hydrochloride, romodepsin, denosumab, hydroxiurea, sipuleucel-T, abiraterone acetate, brentuximab vedotin, crizotinib, ipilumab, ruxolinitib phosphate, vandetanib, vemurafenig, pertuzumab, axitinib, bosutinib, cabozantinib, cafilzomib, enzalutamide, ponatinib hydrochloride, regorafenib, vismodegib, Ziv-aflibercept, dabrafenib, trametinib, obinutuzumam, ado-trastuzumab emtansine, afatinib, pomalidomide, idelalisib, belinostat, ceritinib, avelumab, durvalumab, cemiplimab, dostarlimab, pembrolizumab, ramuricumab, lanreotide, blinatumomab, nivolumab, olaparib, atezolizumab, ipilimumab, Mechlorethamine, Mercaptopurine, Busulfan, Chlorambucil, Cyclophosphamide, Vincristine sulfate, dactinomycin, vinblastine sulfate, thioguanine, procarbazine hydrochloride, floxuridine, fluorouracil, mitotane, bleomycin, doxorubicin hydrochloride, dacarbazine, lomustine, carmustine, cisplatin, asparaginase, streptozocin, etoposide, ifosfamide, carboplatin, altreatime, fludarabine, pentostatin, paclitaxel, melphalan, teniposide, caldribine, vinorelbine tartrate, pegaspargase, thiotepa, docetaxel, gemcitabine, irinotecan, topotecan hydrochloride, idarubicin, capecitabine, daunorubucin hydrochloride, valrubicin, temozolomide, cytarabine, epirubicin, arsenic trioxide, mitomycin, oxaliplatin, pemetrexed disodium, clorabine, nelarabine, ixabepilone, bendamustine hydrochloride, pralatrexate, cabazitaxel, eribuline mesylate, asparaginase erwinia chrysanthemi, oamcetaxine mepesuccinate, radium 223 dichloride, Amikacin, Gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, streptomycin, spectinomycin, geldanamycin, herbimycin, rifaximin, loracarbef, ertapenem, doripenem, imipenem, cilastatin, meropenem, cefadroxil, cefazolin, cephradine, cephrapirin, cephalothin, cefalexin, cefaclor, cefoxitin, cefotetan, cefamandole, cefmetazole, cefonicid, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, ceforeprazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, moxalactam, ceftriaxone, cefepime, ceftaroline fosamil, ceftobirprole, teicoplanin, vancomycin, telavancin, dalbavancin, oritavancin, clindamycin, lincomycin, daptomycin, azithormycin, clarithromycin, erythromycin, roxithromycin, telithromycin, spriamycin, fidaxomicin, aztreonam, furazolidone, nitrodurantoin, linezolid, posizolid, radezolid, torezolid, amoxicillin, ampicillin, azlocillini, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin, piperacillin, temocillin, ticarcillin, bacitracin, colistin, polymyxin, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nadifloxacin, nalidixic acid, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, temfloxacin, mafenied, sulfacetamibed, sulfadiazine, silver sulfadiazine, sulfadimethozine, sulfamethizole, sulfamethoxazole, sulfanilimide, sulfisoxazole, trimehoprim-sulfamethoxazole, sulfonamidochrysoidine, demeclocycline, doxycycline, metacycline, minocyclinie, oxytetracycline, tetracycline, clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinmide, rifampicin, rifabutin, rifapentine, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin, thiampehnicol, tigecycline, tinidazole, tremethoprim, teixobactin, malacidins, halicin, fluticasone propionate, budesonide, ciclesonide, beclomethasone, mometasone, fluticasone furorate, montelukast, zafirlukast, zileuton, fluticasone-salmeterol, budesonide-formoterole, formoterol-mometasone, fluticasone furoate- vilanterol, Theophylline, methylprednisolone, ipratropium, tiotropium, Colchicine, canakinumab, rilonacept, siltuximab, olokizumab, elsilimomab, clazakizumab, sirukumab, levilimab, or any combination thereof. In some embodiments, a drug that can be used in the sense of the invention is one or more of corticosteroids, methotrexate, IL-6 inhibitors, TNF- alpha inhibitors, PD-1 / PD-L1 inhibitors, or CTLA-4 inhibitors. In some embodiments, the drug is an anti-CRP antibody. In some embodiments the drug is an anti-CRP sdAb of the present invention. In some embodiments the drug is one or more of the anti-CRP sdAb as defined in SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. In some embodiments the drug is two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve of the anti-CRP sdAb as defined in SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 1. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 9. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 17. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 25. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 33. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 41. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 49. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 57. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 65. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 73. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 81. In some embodiments, the drug is the anti-CRP sdAb as defined in SEQ ID NO: 89. The features described herein above regarding the apparatus including the first and second unit apply mutatis mutandis to the apparatus comprising a third unit. Accordingly, the invention provides in one aspect an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and (iv) a dispensing unit for dispensing a drug. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and (iv) a dispensing unit for dispensing a drug. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and (iv) a third unit comprising a dispensing unit for dispensing a drug. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and (iv) a third unit comprising a dispensing unit for dispensing a drug. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a sample with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and (iv) a third unit comprising a dispensing unit for dispensing a drug, wherein the drug is one or more of an anti-CRP sdAb of the present invention. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the invention, and (ii) a first unit comprising a contacting unit for contacting a subject with the anti-CRP sdAb, and (iii) a second unit comprising a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and (iv) a third unit comprising a dispensing unit for dispensing a drug, wherein the drug is one or more of an anti-CRP sdAb of the present invention. The apparatus of the present invention can be in form of an applicator like appliance, such as a handheld or stationary device comprising the biosensor of the present invention, or can be permanently or reversibly implanted or attached to the subject’s body, such as an implanted, wearable device comprising the biosensor of the present invention. The implanted or attached apparatus may have a shape of lancet and may be implanted in the dermis layer of the skin e.g. of a subject for detecting binding of the anti-CRP sdAb of the present invention to CRP, e.g. by contacting a sample, e.g. interstitial fluid (ISF) with the anti-CRP sdAb. The thereby detected level of CRP may be correlated and / or converted to overall CRP levels in e.g. blood or other bodily fluids. The site and depth of implantation may affect the shape of the implanted or attached apparatus, components, and configuration of the apparatus. The apparatus may be attached or implanted using an insertion mechanism. The signal readout, i.e. detection of CRP level, can be performed by the apparatus. The apparatus can send the results, i.e. detected CRP levels, to any external device, e.g. a server or smartphone, optionally via an application. The advantage of having a reversibly or permanently implanted apparatus is that continuous measurement of CRP is enabled which can increase the reliability of the obtained CRP dynamics over time. This can be especially useful if the apparatus is to be used for disease management and treatment decisions in a subject, e.g. in combination with the in vivo diagnosis or methods of monitoring the level of CRP described herein below. A reversibly or permanently implanted apparatus can for example detect inflammation spikes in a subject and indicate when medication is necessary and what amount of medication is necessary, thereby greatly improving management of an inflammatory disease in a subject. In a further embodiment, an apparatus as described above can detect when medication is necessary and what amount of medication is necessary and dispense the necessary amount at the relevant time into the subject’s circulatory system. The apparatus can establish the temporal variable (time when medication is necessary) by detecting that a certain threshold of CRP level is overcome, such as a reference value as described herein. The apparatus can establish the quantitative variable (necessary amount of medication) by detecting the difference of the CRP level measured in the subject and the reference value as described herein. The above similarly applies to an apparatus of the present invention in form of an applicator like appliance. Applicator like appliance means that the apparatus is not reversibly or permanently attached to or implanted into a subject. It is rather used as a device on the subject’s body to obtain a single measurement at a time (spot measurement). The apparatus used in this way can indicate when and if the measurement is indicative that medication is necessary and can indicate what amount of medication is necessary like explained above, i.e. by comparing the measurements with a reference value. As mentioned herein, the apparatus of the present invention can comprise the biosensor of the present invention. In such a case, the biosensor could be seen as a subsystem within the apparatus. The apparatus of the present invention can also be partially implanted. For example the biosensor subsystem of the apparatus may be the implanted part, i.e. being within the body of a subject (under the skin layer). The entire apparatus does not necessarily have to be entirely within the body (under the skin layer) but can also be superficially attached e.g. on the skin. In such a setup the signal readout electronics is wearable (e.g. being superficially attached on the skin of the subject) and connected with the implanted part, e.g. the biosensor. When the apparatus is an applicator like appliance, e.g. for the “ spot measurement system” it can comprise a biosensor strip (e.g. on a bench), and a portable electronics reader that can be connected to the biosensor strip or vice versa to provide a readout. Accordingly, the invention provides in one aspect an apparatus comprising: (i) an anti-CRP sdAb of the present invention, and (ii) a contacting unit for contacting a sample or a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and optionally (iv) a dispensing unit for dispensing a drug, optionally wherein the drug is the anti-CRP sdAb of the present invention, wherein the apparatus is reversibly attached to or implanted into the subject. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the present invention, and (ii) a contacting unit for contacting a sample or a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and optionally (iv) a dispensing unit for dispensing a drug, optionally wherein the drug is the anti-CRP sdAb of the present invention, wherein the apparatus is permanently attached to or implanted into the subject. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the present invention, and (ii) a contacting unit for contacting a sample or a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and optionally (iv) a dispensing unit for dispensing a drug, optionally wherein the drug is the anti-CRP sdAb of the present invention, wherein the apparatus is fully or partially implantable. In another aspect, the invention provides an apparatus comprising: (i) an anti-CRP sdAb of the present invention, and (ii) a contacting unit for contacting a sample or a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and optionally (iv) a dispensing unit for dispensing a drug, optionally wherein the drug is the anti-CRP sdAb of the present invention, wherein the apparatus is fully or partially implanted into a subject. Any of apparatuses as described herein can be permanent, reusable, single use, disposable or for temporary use (e.g. implant). For example, a biosensor of the present invention can be implanted for a limited time e.g.14 days for a continuous measurement of CRP level. In yet another aspect, the invention provides the following items: 1. An apparatus (for detecting a target analyte) comprising: (i) a collector for collecting a sample, (ii) a sensing component comprising a biosensor comprising an anti-CRP sdAb of the present invention, (iii) a connector for connecting the sensing component to an electrochemical measurement device. 2. The apparatus of item 1, wherein the collector is designed to at least partially encase the sensing component. The apparatus of item 1 or 2, wherein the collector comprises a first portion and a second portion, the first portion being able to contain the collected sample and the second portion encasing the sensing component. The apparatus of item 3, wherein the first portion comprises a nozzle and a sampling reservoir. The apparatus of item 4, wherein the nozzle comprises microfluidic channels optionally treated with a hydrophilic coating. The apparatus of item 4, wherein the nozzle comprises silica capillary tubes. The apparatus of any one of items 1-6, wherein the collector and the connector are provided with complementary locking means to secure the sensing component within the device. The apparatus of any one of items 1-7, wherein the sensing component further comprises two working electrodes, a counter electrode and a reference electrode. The apparatus of item 8, wherein the electrode of the biosensor and the two working electrodes comprise gold. The apparatus of items 8 or 9, wherein the counter electrode comprises platinum and the reference electrode comprises silver. The apparatus of items 8-10, wherein each electrode is in the form of a wire. The apparatus of item 11, wherein the sensing component has a cylindrical form and the wires are positioned spaced apart within the sensing component along a length thereof. The apparatus of any one of items 8-12, wherein the electrodes are held in a matrix of a non-conductive material. The apparatus of item 13, wherein the non-conductive material comprises a silicon resin. 15. The apparatus of item any one of items 11-14, wherein the anti-CRP sdAb is bound to a first end of the biosensor electrode wire and the anti-CRP sdAb is exposed to the sample when the first end is in contact with the collected sample. 16. The apparatus of any one of items 11-15, wherein a first end of each electrode wire is in contact with the sample when collected in the collector. 17. The apparatus of any one of items 11-15, wherein a second end of the wires are in contact with the connector. 18. The apparatus of any one of items 1-17, wherein the sample comprises a biological fluid, such as a bodily fluid e.g. interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva. 19. The apparatus of any one of items 1-18, wherein the target analyte is CRP. The sdAbs of the present invention are particularly useful for therapy since they can inhibit the biological function of CRP thereby reducing inflammation. The sdAbs of the present invention do not necessarily inhibit the biological function of CRP. In some embodiments, it is preferred that a sdAbs of the invention do not inhibit the biological function of CRP, e.g. when detection but not treatment is desired. Accordingly, in some embodiments it is preferred that a sdAb of the invention does inhibit the biological function of CRP, e.g. when detection and therapy or only therapy is desired. As used herein “treatment” preferably relates to the acute treatment, prophylactic treatment, or the disease management of an inflammatory disease and / or autoimmune disease related to an increased CRP production, CRP secretion, CRP release or CRP level or increased inflammation values that are treated with the anti-CRP sdAbs of the invention. Accordingly, the present invention provides in one aspect an anti-CRP sdAb of the invention for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 1 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 9 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 17 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 25 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 33 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 41 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 49 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 57 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 65 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 73 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 81 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in SEQ ID NO: 89 for use as a medicament. In another aspect, the invention provides the anti-CRP sdAb as defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 for use as a medicament. In another aspect, the invention provides one or more, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAbs as defined in SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 for use as a medicament. Secretion of CRP can induce inflammation. Thus, the sdAbs of the invention are preferably used in the treatment of CRP associated diseases, such as diseases associated with inflammation or systemic inflammation. In particular, the disease may be associated with an increased production or release of CRP. Inhibiting the biological function of CRP can thus ameliorate this effect and reduce the resulting inflammation. The invention is not particularly limited to a disease to be treated, rather any disease that results in increased CRP production, CRP secretion, CRP release or CRP level or increased inflammation values can be treated with the sdAbs of the invention. Such a disease can be associated with an increased production, secretion, release, or level of inflammatory markers. Inflammatory markers can indicate an inflammation event which may then be treated with the anti-CRP sdAbs of the present invention. Exemplary inflammatory markers are Adenosine deaminase (ADA), Artemin (ARTN), Axin-1 (AXIN1), Beta-nerve growth factor (NGF), C-reactive protein (CRP), C-C motif chemokine 13 (CCL13), C-C motif chemokine 19 (CCL19), C-C motif chemokine 2 (CCL2), C-C motif chemokine 20 (CCL20), C-C motif chemokine 23 (CCL23), C-C motif chemokine 25 (CCL25), C-C motif chemokine 28 (CCL28), C-C motif chemokine 3 (CCL3), C-C motif chemokine 4 (CCL4), C- C motif chemokine 7 (CCL7), C-C motif chemokine 8 (CCL8), C-X-C motif chemokine 10 (CXCL10), C-X-C motif chemokine 11 (CXCL11), C-X-C motif chemokine 5 (CXCL5), C-X- C motif chemokine 6 (CXCL6), C-X-C motif chemokine 9 (CXCL9), CUB domain-containing protein 1 (CDCP1), Caspase-8 (CASP8), Cystatin-D (CST5), Delta and Notch-like epidermal growth factor-related receptor (DNER), Eotaxin (CCL11), Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1), Fibroblast growth factor 19 (FGF19), Fibroblast growth factor 21 (FGF21), Fibroblast growth factor 23 (FGF23), Fibroblast growth factor 5 (FGF5), Fms-related tyrosine kinase 3 ligand (FLT3LG), Fractalkine (CX3CL1), Glial cell line- derived neurotrophic factor (GDNF), Growth-regulated alpha protein (CXCL1), Hepatocyte growth factor (HGF), Interferon gamma (IFNG), Interleukin-1 alpha (IL1A), Interleukin-10 (IL10), Interleukin-10 receptor subunit alpha (IL10RA), Interleukin-10 receptor subunit beta (IL10RB), Interleukin-12 subunit beta (IL12B), Interleukin-13 (IL13), Interleukin-15 receptor subunit alpha (IL15RA), Interleukin-17A (IL17A), Interleukin-17C (IL17C), Interleukin-18 (IL18), Interleukin-18 receptor 1 (IL18R1), Interleukin-2 (IL2), Interleukin-2 receptor subunit beta (IL2RB), Interleukin-20 (IL20), Interleukin-20 receptor subunit alpha (IL20RA), Interleukin-22 receptor subunit alpha-1 (IL22RA1), Interleukin-24 (IL24), Interleukin-33 (IL33), Interleukin-4 (IL4), Interleukin-5 (IL5), Interleukin-6 (IL6), Interleukin-7 (IL7), Interleukin-8 (CXCL8), Interstitial collagenase (MMP1), Kit ligand (KITLG), Leukemia inhibitory factor (LIF), Leukemia inhibitory factor receptor (LIFR), Lymphotoxin-alpha (LTA), Macrophage colony-stimulating factor 1 (CSF1), NAD-dependent protein deacetylase sirtuin-2 (SIRT2), Natural killer cell receptor 2B4 (CD244), Neurotrophin-3 (NTF3), Neurturin (NRTN), Oncostatin-M (OSM), Programmed cell death 1 ligand 1 (CD274), Protein S100-A12 (S100A12), Protransforming growth factor alpha (TGFA), STAM-binding protein (STAMBP), Signaling lymphocytic activation molecule (SLAMF1), Stromelysin-2 (MMP10), Sulfotransferase 1A1 (SULT1A1), T-cell differentiation antigen CD6 (CD6), T-cell surface glycoprotein CD5 (CD5), T-cell surface glycoprotein CD8 alpha chain (CD8A), Thymic stromal lymphopoietin (TSLP), Transforming growth factor beta-1 proprotein (TGFB1), Tumor necrosis factor alpha (TNF-a), Tumor necrosis factor ligand superfamily member 10 (TNFSF10), Tumor necrosis factor ligand superfamily member 11 (TNFSF11), Tumor necrosis factor ligand superfamily member 12 (TNFSF12), Tumor necrosis factor ligand superfamily member 14 (TNFSF14), Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), Tumor necrosis factor receptor superfamily member 5 (CD40), Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), Urokinase-type plasminogen activator (PLAU), Vascular endothelial growth factor A (VEGFA) and the like or any combination thereof. Inflammatory markers can also include the following markers. Exemplary additional biomarkers are: Adiponectin, CD44var (v6), Elafin, Lactoferrin, MMP-3, NRP-1, RANTES (CCL5), Resistin (ADSF), VCAM-1, CD14, CD62L (L-Selectin), Endoglin, Leptin, MMP-9, Osteopontin (OPN), RBP4, SCGF beta, ZAG, CD44, Cystatin C, ICAM-1, MBL, NGAL, PAI- 1 (Serpin), REG-3a, TIMP-1. Additionally, markers can indicate vascular injuries. Exemplary vascular injury markers are Serum Amyloid A, C-Reactive Protein CRP, Vascular Cell Adhesion Molecule-1 (VCAM- / CD106), Intercellular Adhesion Molecule-1 (ICAM-1 / CD54). In a preferred embodiment an inflammatory marker is CRP. Exemplary diseases are inflammatory diseases and / or autoimmune diseases. Exemplary inflammatory diseases and / or autoimmune diseases are rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, tumour and the like. Accordingly, the invention provides in one aspect an anti-CRP sdAb of the invention for use in the treatment of a disease associated with an inflammation. In another aspect, the invention provides an anti-CRP sdAb of the invention for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation. It is also envisioned herein that the anti-CRP sdAb of the invention can be used in co-therapy, wherein more than one, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb are selected from SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89. Accordingly, the invention provides two or more, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb selected form SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation. Accordingly, the invention provides in one aspect one or more anti-CRP sdAb selected from the group of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation. In general, it is envisioned that sdAbs of the present invention can also be used in combination, e.g. sdAbs having specific kon / koffvalues can be combined to achieve coverage of continuous and reversible binding over a desired dynamic range of e.g. CRP. In another aspect, the invention provides an anti-CRP sdAb of the invention for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation, wherein the disease is associated with an increased production or release of inflammatory markers. In another aspect, the invention provides an anti-CRP sdAb of the invention for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation, wherein the disease is associated with an increased production or release of CRP. In another aspect, the invention provides an anti-CRP sdAb of the invention for use in the treatment of an inflammatory and / or autoimmune disease. In another aspect, the invention provides an anti-CRP sdAb of the invention for use in the treatment of rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, or tumour. Methods of treatment are also envisioned herein. In general, the features described in context of the anti-CRP sdAb of the present invention for use in the treatment of a disease also apply to the methods of treatment provided herein. The method of treatment can comprise a step of administering one or more anti-CRP sdAb of the invention to a subject. Similarly, co-therapy can be practiced in a method of treatment, wherein more than one, such as two, three, four, five, six, seven, eight, nine, ten, eleven or twelve anti-CRP sdAb selected from SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 are administered to a subject. Accordingly, the invention provides in one aspect a method of treatment comprising a step of administering an anti-CRP sdAb of the invention to a subject in need thereof. In another aspect, the invention provides a method of treatment comprising a step of administering one or more of an anti-CRP sdAb selected from the group of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 to a subject in need thereof. In another aspect, the invention provides a method of treatment comprising a step of administering two or more of an anti-CRP sdAb selected from the group of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, or 89 to a subject in need thereof. In another aspect, the invention provides a method of treatment comprising a step of administering an anti-CRP sdAb of the invention to a subject in need thereof, wherein the subject suffers from a disease associated with an increased production or release of inflammatory markers. In another aspect, the invention provides a method of treatment comprising a step of administering an anti-CRP sdAb of the invention to a subject in need thereof, wherein the subject suffers from a disease associated with an increased production or release of CRP. In another aspect, the invention provides a method of treatment comprising a step of administering an anti-CRP sdAb of the invention to a subject in need thereof, wherein the subject suffers from an inflammatory and / or autoimmune disease. In another aspect, the invention provides a method of treatment comprising a step of administering an anti-CRP sdAb of the invention to a subject in need thereof, wherein the subject suffers from rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, ...
Claims
New PCT-Patent Application Seerave Enterprises Limited, Christopher Rees Vossius Ref.: AF2045 PCT BS CLAIMS 1. An anti-C-reactive protein (CRP) single-domain antibody (sdAb) comprising an on-rate constant (kon) of about or more than about 2.1 x 10^5 s-1M-1, an off-rate constant (koff) of about 2.5 x 10^-9 s-1– 2 x 10^-1 s-1, and / or a dissociation constant (KD) of about less than about 1 x 10^-8 M, preferably wherein said sdAb is capable of detecting and / or quantifying CRP concentrations of about 0.01 µM or less to about 1 µM or more.
2. The anti-CRP sdAb of claim 1, wherein the sdAb comprises a first complementary determining region (CDR1), a second CDR (CDR2) and third CDR (CDR3), wherein: (i) CDR1 comprises SEQ ID NO: 3 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 5 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 7 or a variant thereof having up to five amino acid substitutions; or (ii) CDR1 comprises SEQ ID NO: 11 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 13 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 15 or a variant thereof having up to five amino acid substitutions; or (iii) CDR1 comprises SEQ ID NO: 19 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 21 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 23 or a variant thereof having up to five amino acid substitutions; or (iv) CDR1 comprises SEQ ID NO: 27 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 29 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 31 or a variant thereof having up to five amino acid substitutions; or (v) CDR1 comprises SEQ ID NO: 35 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 37 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 39 or a variant thereof having up to five amino acid substitutions; or (vi) CDR1 comprises SEQ ID NO: 43 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 45 or a variant thereof havingup to two amino acid substitutions, CDR3 comprises SEQ ID NO: 47 or a variant thereof having up to five amino acid substitutions; (vii) CDR1 comprises SEQ ID NO: 51 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 53 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 55 or a variant thereof having up to five amino acid substitutions; or (viii) CDR1 comprises SEQ ID NO: 59 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 61 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 63 or a variant thereof having up to five amino acid substitutions; or (ix) CDR1 comprises SEQ ID NO: 67 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 69 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 71 or a variant thereof having up to five amino acid substitutions; or (x) CDR1 comprises SEQ ID NO: 75 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 77 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 79 or a variant thereof having up to five amino acid substitutions; or (xi) CDR1 comprises SEQ ID NO: 83 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 85 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 87 or a variant thereof having up to five amino acid substitutions; or (xii) CDR1 comprises SEQ ID NO: 91 or a variant thereof having up to two amino acid substitutions, CDR2 comprises SEQ ID NO: 93 or a variant thereof having up to two amino acid substitutions, CDR3 comprises SEQ ID NO: 95 or a variant thereof having up to five amino acid substitutions.
3. The anti-CRP sdAb of claim 1 or 2, wherein the sdAb comprises a first framework region (FR1), a second framework region (FR2) and third framework region (FR3), wherein: (i) FR1 comprises SEQ ID NO: 2 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 4 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 6 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 8 or a variant thereof having up to three amino acid substitutions; or (ii) FR1 comprises SEQ ID NO: 10 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 12 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 14 or a variantthereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 16 or a variant thereof having up to three amino acid substitutions; or (iii) FR1 comprises SEQ ID NO: 18 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 20 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 22 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 24 or a variant thereof having up to three amino acid substitutions; or (iv) FR1 comprises SEQ ID NO: 26 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 28 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 30 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 32 or a variant thereof having up to three amino acid substitutions; or (v) FR1 comprises SEQ ID NO: 34 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 36 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 38 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 40 or a variant thereof having up to three amino acid substitutions; or (vi) FR1 comprises SEQ ID NO: 42 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 44 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 46 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 48 or a variant thereof having up to three amino acid substitutions; or (vii) FR1 comprises SEQ ID NO: 50 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 52 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 54 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 56 or a variant thereof having up to three amino acid substitutions; (viii) FR1 comprises SEQ ID NO: 58 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 60 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 62 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 64 or a variant thereof having up to three amino acid substitutions; or (ix) FR1 comprises SEQ ID NO: 66 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 68 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 70 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 72 or a variant thereof having up to three amino acid substitutions; or (x) FR1 comprises SEQ ID NO: 74 or a variant thereof having up to six amino acidsubstitutions, FR2 comprises SEQ ID NO: 76 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 78 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 80 or a variant thereof having up to three amino acid substitutions; or (xi) FR1 comprises SEQ ID NO: 82 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 84 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 86 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 88 or a variant thereof having up to three amino acid substitutions; or (xii) FR1 comprises SEQ ID NO: 90 or a variant thereof having up to six amino acid substitutions, FR2 comprises SEQ ID NO: 92 or a variant thereof having up to four amino acid substitutions, FR3 comprises SEQ ID NO: 94 or a variant thereof having up to ten amino acid substitutions, and FR4 comprises SEQ ID NO: 96 or a variant thereof having up to three amino acid substitutions.
4. The anti-CRP sdAb of any one of claims 1 to 3, wherein the sdAb comprises any one of (i) SEQ ID NO: 1 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 1; or (ii) SEQ ID NO: 9 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 9; or (iii) SEQ ID NO: 17 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 17; or (iv) SEQ ID NO: 25 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 25; or (v) SEQ ID NO: 33 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 33; or (vi) SEQ ID NO: 41 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 41; or (vii) SEQ ID NO: 49 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 49; or (viii) SEQ ID NO: 57 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 57; or (ix) SEQ ID NO: 65 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 65; or (x) SEQ ID NO: 73 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 73; or (xi) SEQ ID NO: 81 or a variant thereof having at least about 90% sequence identity to SEQ ID NO: 81; or(xii) SEQ ID NO: 89 or a variant thereof having at least about 90% sequence identity to SEQ ID NO:
89.
5. The anti-CRP sdAb of any one of claims 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 1.30 x 10^-2 s-1.
6. The anti-CRP sdAb of any one of claims 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 4.60 x 10^6 s-1M-1and an off-rate constant (koff) of about 2.60 x 10^-4 s-1– 2.20 x 10^-1 s-1.
7. The anti-CRP sdAb of any one of claims 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 4.10 x 10^4 s-1M-1– 3.80 x 10^5 s-1M-1and an off-rate constant (koff) of about 2.00 x 10^-5 s-1– 6.90 x 10^-3 s-1.
8. The anti-CRP sdAb of any one of claims 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.70 x 10^7 s-1M-1± 9.06 x 10^2 s- – 3.00 x 10^5 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 1.30 x 10^-2 s-1± 1.34 x 10^-7 s-1– 8.82 x 10^-5 s-1and optionally a KDof about 1.00 x 10^- 2 M – 9.62 M, optionally wherein the values are obtained by a SPR Biacore binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89.
9. The anti-CRP sdAb of any one of claims 1-4, wherein the anti-CRP sdAb comprises an on-rate constant (kon) of about 4.10 x 10^4 s-1M-1– 3.80 x 10^5 s-1M-1± 3.31 x 10^2 s- – 1.48 x 10^4 s-1M-1and an off-rate constant (koff) of about 2.00 x 10^-5 s-1– 6.90 x 10^-3 s-1± 1.41 x 10^-6 s-1– 8.61 x 10^-5 s-1and optionally a KDof about 5.80 x 10^- 11 M – 6.50 x 10^-8 M, optionally wherein the values are obtained by an Octet BLI binding kinetic measurement, preferably wherein the sdAb is defined in any one of SEQ ID NOs: 1, 9, 17, 25, 33, 49, 57, 65, 73, 81, 89.
10. The anti-CRP sdAb of any one of claims 1-9, wherein the anti-CRP sdAb continuously and reversibly binds CRP.
11. The anti-CRP sdAb of any one of claims 1-10, wherein the anti-CRP sdAb binds a second or further CRP after dissociating from a first CRP.
12. The anti-CRP sdAb of any one of claims 1-11, wherein the anti-CRP sdAb inhibits thebiological function of CRP.
13. The anti-CRP sdAb of any one of claims 1-11, wherein the anti-CRP sdAb does not inhibit the biological function of CRP.
14. The anti-CRP sdAb of claim 12 or 13, wherein the biological function of CRP is CRP signalling or the CRP signalling pathway.
15. The anti-CRP sdAb of any one of claims 1-14, wherein the anti-CRP sdAb is conjugated to a biosensor electrode, such as a working electrode.
16. The anti-CRP sdAb of claim 15, wherein the anti-CRP sdAb is conjugated to a biosensor electrode via a linker, such as a nucleic acid.
17. The anti-CRP sdAb of claim 15 or 16, wherein the biosensor comprises one or more electrode, such as a working electrode and / or a counter electrode and / or a reference electrode, and a substrate.
18. The anti-CRP sdAb of any one of claims 15-17, wherein the biosensor comprises at least a working electrode and a substrate.
19. The anti-CRP sdAb of any one of claims 15-18, wherein the biosensor comprises an electrode comprising a conductive material such as carbon, metal, or metallic compound.
20. The anti-CRP sdAb of any one of claims 1-19, wherein the anti-CRP sdAb further comprises a detection label or tag.
21. The anti-CRP sdAb of any one of claims 1-19, wherein the anti-CRP sdAb does not comprise a detection label or tag.
22. A nucleic acid encoding the anti-CRP sdAb of any one of claims 1-21.
23. A vector comprising the nucleic acid of claim 22.
24. The vector of claim 23, wherein the vector is an expression vector.
25. A method for detecting and / or quantifying CRP in a sample, the method comprising:(i) contacting a sample with the anti-CRP sdAb of any one of claims 1-21, and (ii) detecting binding of the anti-CRP sdAb.
26. An in situ method for detecting and / or quantifying CRP in a subject, the method comprising (i) contacting a subject’s biological fluid with the anti-CRP sdAb of any one of claims 1-21; and (ii) detecting binding of the anti-CRP sdAb.
27. The method of claim 25 or 26, further comprising detecting the binding of the anti-CRP sdAb over time.
28. The method of any one of claims 25-27, further comprising detecting the repeated binding of the anti-CRP sdAb over time.
29. The method of any one of claims 25-28, wherein binding of the anti-CRP sdAb is detected by a biosensor.
30. The method of any one of claims 25-29, wherein the sample comprises a biological fluid, such as a bodily fluid, for example interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva; or wherein the biological fluid is a bodily fluid, for example interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva.
31. The method of any one of claims 25-30, wherein the sample comprises human interstitial fluid (ISF), blood, urine, stool, serum, tear, sweat or saliva, or wherein the biological fluid is a human bodily fluid, for example human interstitial fluid (ISF), blood, urine, stool, serum, tear fluid, sweat or saliva.
32. The method of any one of claims 25and 27-29, wherein the sample comprises a sample from a biological production system such as a culture sample.
33. The anti-CRP sdAb of any one of claims 1-21 for use as a medicament.
34. The anti-CRP sdAb of any one of claims 1-21 for use in in vivo diagnosis.
35. The anti-CRP sdAb of any one of claims 1-21 for use in the treatment of a disease associated with an inflammation, optionally a systemic inflammation.
36. A method of treatment a disease associated with an inflammation, optionally a systemic inflammation comprising a step of administering the anti-CRP sdAb of any one of claims 1-21 to a subject in need thereof.
37. The anti-CRP sdAb for use of claim 35, or the method of claim 36, wherein the disease is associated with an increased production or release of inflammatory markers.
38. The anti-CRP sdAb for use of claim 35 or 37, or the method of claim 36 or 37, wherein the disease is associated with an increased production or release of CRP.
39. The anti-CRP sdAb for use of any one of claims 35 or 37-38, or the method of any one of claims 36-38, wherein the disease is rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, or tumour.
40. The anti-CRP sdAb of any one of claims 1-21 for use in a method of in vivo diagnosis of a disease associated with an inflammation, optionally a systemic inflammation, the method comprising: (i) contacting a subject with the anti-CRP sdAb of any one of claims 1-21, and (ii) detecting the binding of the anti-CRP sdAb.
41. A method of in vivo diagnosis of a disease associated with an inflammation, optionally a systemic inflammation, the method comprising: (i) contacting a subject with the anti-CRP sdAb of any one of claims 1-21, and (ii) detecting binding of the anti-CRP sdAb.
42. An ex vivo or in vitro method of monitoring the level of CRP comprising: (i) contacting a sample of a subject with the anti-CRP sdAb of any one of claims 1- 21, and (ii) detecting binding of the anti-CRP sdAb.
43. A method of monitoring the level of CRP in a subject comprising: (i) contacting the subject with the anti-CRP sdAb of any one of claims 1-21, and (ii) detecting binding of the anti-CRP sdAb.
44. The anti-CRP sdAb for use of claims 35 or 37-40, or the method of any one of claims 36-39 or 41-43, wherein binding of the anti-CRP sdAb is repeatedly detected over time.
45. An apparatus comprising: (i) the anti-CRP sdAb of any one of claims 1-21, and (ii) a contacting unit for contacting a sample or a subject with the anti-CRP sdAb, and (iii) a detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb, and optionally (iv) a dispensing unit for dispensing a drug, optionally wherein the drug is the anti- CRP sdAb of any one of claims 1-21.
46. The apparatus of claim 45 for use in the treatment or in vivo diagnosis of a disease associated with an inflammation, optionally a systemic inflammation.
47. The apparatus of claim 45 or the apparatus for use of claim 46, wherein the detecting unit for detecting and / or quantifying binding of the anti-CRP sdAb comprises a biosensor.
48. The apparatus or the apparatus for use of claim 47, wherein the biosensor comprises one or more electrode, such as a working electrode and / or a counter electrode and / or a reference electrode, and a substrate, optionally wherein the sdAb is conjugated to the working electrode.
49. The apparatus or the apparatus for use of claim 47 or 48, wherein the biosensor comprises at least a working electrode and a substrate.
50. The apparatus or the apparatus for use of any one of claims 47-49, wherein the biosensor comprises an electrode comprising a conductive material such as carbon, a metal or metallic compound.
51. The apparatus or the apparatus for use of any one of claims 48-50, wherein the anti-CRP sdAb is layered on the one or more electrode or conjugated to the one or more electrode, preferably the working electrode and optionally, wherein the anti-CRP sdAb isconjugated to said electrode via a linker.
52. The anti-CRP sdAb for use of claim 35 or 40, or the method of claim 36 or 41, or the apparatus for use of any one of claims 46-51, wherein the disease is associated with an increased production or release of inflammatory markers.
53. The anti-CRP sdAb for use of any one of claims 35, 40 or 52, or the method of any one of claims 36, 41 or 52, or the apparatus for use of any one of claims 46-52, wherein the disease is associated with an increased production or release of CRP.
54. The anti-CRP sdAb for use of any one of claims 35, 40 or 52-53, or the method of any one of claims 36, 41 or 52-53, or the apparatus of any one of claims 46-53, wherein the disease is any one of rheumatoid arthritis, inflammatory bowel disease, IgA nephropathy, Psoriasis, lupus, multiple sclerosis, Endometriosis, Sepsis, cardiovascular disease, metabolic syndrome, hypertension, diabetes, cancer, bacterial or viral infections, COVID19, asthma, familial Mediterranean fever, Alzheimer’s disease, Parkinson’s diseases, diabetic macular edema (DME), diabetic retinopathy, uveitis, glaucoma, dry eye (e.g., dry eye disease or dry eye syndrome), allergic conjunctivitis, ocular pain, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), neuromyelitis optica (NMO), corneal transplant, corneal abrasion, physical injury to the eye, non-alcoholic fat liver disease, chronic kidney disease, or tumour.
55. A method of producing an anti-CRP sdAb comprising: (i) contacting a subject with a recombinant human CRP, and (ii) isolating a sdAb which successfully binds to CRP, and (iii) selecting for an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 2.20 x 10^-1 s-1.
56. The method of claim 55, wherein the method comprises selecting for an on-rate constant (kon) of about 3.80 x 10^5 s-1M-1– 1.70 x 10^7 s-1M-1and an off-rate constant (koff) of about 3.20 x 10^-9 s-1– 1.30 x 10^-2 s-1.
57. The method of claim 55, wherein the method comprises selecting for an on-rate constant (kon) of about 3.30 x 10^4 s-1M-1– 4.60 x 10^6 s-1M-1and an off-rate constant (koff) of about 2.60 x 10^-4 s-1– 2.20 x 10^-1 s-1.
58. The method of claim 55, wherein the method comprises selecting for an on-rate constant(kon) of about 4.10 x 10^4 s-1M-1– 3.80 x 10^5 s-1M-1and an off-rate constant (koff) of about 2.00 x 10^-5 s-1– 6.90 x 10^-3 s-1.
59. The method of any one of claims 55-58, wherein the method further comprises a step of selecting for continuous and reversible binding to CRP.
60. The method of any one of claims 55-59, wherein the method further comprises a step of selecting for binding to a second or further CRP after dissociation from a first CRP.
61. The method of any one of claims 55-60, wherein the method further comprises a step of selecting for inhibiting the biological function of CRP or not inhibiting the biological function of CRP.
62. The method of claim 61, wherein the biological function of CRP is CRP signalling or the CRP signalling pathway.
63. An anti-CRP sdAb produced by the method of any one of claims 55-62.
64. A biosensor comprising the anti-CRP sdAb of any one of claims 1-21.
65. The biosensor of claim 64, wherein the biosensor comprises one or more biosensor electrodes.
66. The biosensor of claim 64 or 65, wherein the biosensor comprises a working electrode and a substrate 67. The biosensor of claim 66, wherein the biosensor further comprises a counter electrode and / or a reference electrode.
68. The biosensor of any one of claims 64-67, wherein the anti-CRP sdAb is conjugated to a biosensor electrode, optionally to a working electrode.
69. The biosensor of claim 68, wherein the anti-CRP sdAb is conjugated to a biosensor electrode, optionally to a working electrode, via a linker, such as a nucleic acid linker, amino acid / peptide linker, peptide nucleic acid linker, polymer linker, polyethylenglycol (PEG) linker, protein-tag linker, or conventional chemistry technique linker.
70. The biosensor of any one of claims 66-69, wherein the working electrode comprises a conductive material, such as carbon, metal or metallic compound.
71. The biosensor of any one of claims 64-70, wherein the biosensor, the anti-CRP sdAb or the linker comprises a detection label, a tag, or redox reporters / indicators.
72. The method of any one of claims 25-32, 36-39 or 41-44, or the anti-CRP sdAb for use of any one of claims 35, 37-40 or 44, wherein binding of the anti-CRP sdAb to CRP is detected and / or quantified by electrochemical ELISA.
Citation Information
Patent Citations
Anti-c reactive protein antibody, biosensor using the same antibody, method for preparing the same antibody and method for measuring immunity by using the same antibody
JP2004189665A
Cited By
CRP camel source single-domain antibody as well as preparation method and application thereof
CN116217723A
A CRP camel-derived single-domain antibody, its preparation method and application
CN116217723B
CRP camel source single-domain antibody as well as preparation method and application thereof
CN116239686A
A camelid single-domain antibody against crp and its preparation method and application
CN116239686B
CRP camel source single-domain antibody as well as preparation method and application thereof
CN116239687A
